bioRxiv preprint doi: https://doi.org/10.1101/2020.06.25.172403. this version posted July 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor

3

Peng Zhao^{1,#}, Jeremy L. Praissman^{1,#}, Oliver C. Grant^{1,#}, Yongfei Cai², Tianshu Xiao², Katelyn E.
Rosenbalm¹, Kazuhiro Aoki¹, Benjamin P. Kellman³, Robert Bridger¹, Dan H. Barouch⁴, Melinda
A. Brindley⁵, Nathan E. Lewis^{3,6}, Michael Tiemeyer¹, Bing Chen², Robert J. Woods^{1*}, and Lance
Wells^{1*}

8

- 9 ¹ Complex Carbohydrate Research Center, Department of Biochemistry and Molecular
- 10 Biology, and Department of Chemistry, University of Georgia, Athens, Georgia, 30602, USA
- 11 ² Division of Molecular Medicine, Children's Hospital and Department of Pediatrics, Harvard
- 12 Medical School, Boston, Massachusetts, 02115, USA
- ³ Departments of Pediatrics and Bioengineering, University of California, San Diego, La Jolla,
- 14 California, 92093, USA
- ⁴ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard
- 16 Medical School, Boston, Massachusetts, 02215, USA
- ⁵ Department of Infectious Diseases, Department of Population Health, Center for Vaccines and
- 18 Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
- ⁶ Novo Nordisk Foundation Center for Biosustainability at UC San Diego, La Jolla, California,
- 20 92093, USA
- 21
- 22 [#] Authors contributed equally
- 23
- ^{*} To whom correspondence should be addressed: Robert J. Woods, <u>rwoods@ccrc.uga.edu</u>,
- and/or Lance Wells, wells@ccrc.uga.edu
- 26
- 27

28 SUMMARY

The current COVID-19 pandemic is caused by the SARS-CoV-2 betacoronavirus, which utilizes its highly glycosylated trimeric Spike protein to bind to the cell surface receptor ACE2 glycoprotein and facilitate host cell entry. We utilized glycomics-informed glycoproteomics to characterize site-specific microheterogeneity of glycosylation for a recombinant trimer Spike mimetic immunogen and for a soluble version of human ACE2. We combined this information with bioinformatic analyses of natural variants and with existing 3D-structures of both glycoproteins to generate molecular dynamics simulations of each glycoprotein alone and interacting with one another. Our results highlight roles for glycans in sterically masking polypeptide epitopes and directly modulating Spike-ACE2 interactions. Furthermore, our results illustrate the impact of viral evolution and divergence on Spike glycosylation, as well as the influence of natural variants on ACE2 receptor glycosylation that, taken together, can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.

42 Keywords: SARS-CoV-2; COVID-19; Spike protein; coronavirus; ACE2; glycoprotein; 43 glycosylation; mass spectrometry; molecular dynamics; 3D-modeling

56 INTRODUCTION

57 The SARS-CoV-2 coronavirus, a positive-sense single-stranded RNA virus, is responsible for the 58 severe acute respiratory syndrome referred to as COVID-19 that was first reported in China in 59 December of 2019 (1). In approximately six months, this betacoronavirus has spread globally 60 with more than 14 million people testing positive worldwide resulting in greater than 600,000 61 deaths as of July 20th, 2020 (https://coronavirus.jhu.edu/map.html). The SARS-CoV-2 62 coronavirus is highly similar (nearly 80% identical at the genomic level) to SARS-CoV-1, which 63 was responsible for the severe acute respiratory syndrome outbreak that began in 2002 (2,3). 64 Furthermore, human SARS-CoV-2 at the whole genome level is >95% identical to a bat 65 coronavirus (RaTG13), the natural reservoir host for multiple coronaviruses (1,4,5). Given the 66 rapid appearance and spread of this virus, there is no current validated vaccine or SARS-CoV-2-67 specific targeting therapy clinically approved although statins, heparin, and steroids look 68 promising for lowering fatality rates and antivirals likely reduce the duration of symptomatic 69 disease presentation (6-12).

70 SARS-CoV-2, like SARS-CoV-1, utilizes the host angiotensin converting enzyme II (ACE2) for 71 binding and entry into host cells (13,14). Like many viruses, SARS-CoV-2 utilizes a Spike 72 glycoprotein trimer for recognition and binding to the host cell entry receptor and for membrane 73 fusion (15). Given the importance of viral Spike proteins for targeting and entry into host cells 74 along with their location on the viral surface, Spike proteins are often used as immunogens for 75 vaccines to generate neutralizing antibodies and frequently targeted for inhibition by small 76 molecules that might block host receptor binding and/or membrane fusion (15,16). In similar 77 fashion, wildtype or catalytically-impaired ACE2 has also been investigated as a potential 78 therapeutic biologic that might interfere with the infection cycle of ACE2 targeting coronaviruses 79 (17,18). Thus, a detailed understanding of SARS-CoV-2 Spike binding to ACE2 is critical for 80 elucidating mechanisms of viral binding and entry, as well as for undertaking the rational design 81 of effective therapeutics.

82 The SARS-CoV-2 Spike glycoprotein consists of two subunits, a receptor binding subunit (S1) 83 and a membrane fusion subunit (S2) (1,2). The Spike glycoprotein assembles into stable 84 homotrimers that together possess 66 canonical sequons for N-linked glycosylation (N-X-S/T, 85 where X is any amino acid except P) as well as a number of potential O-linked glycosylation sites 86 (19,20). Interestingly, coronaviruses virions bud into the lumen of the endoplasmic reticulum-87 Golgi intermediate compartment, ERGIC, raising unanswered questions regarding the precise 88 mechanisms by which viral surface glycoproteins are processed as they traverse the secretory 89 pathway (21.22). While this and similar studies (19.23) analyze recombinant proteins, a previous 90 SARS-CoV-1 suggest that glycosylation of the Spike can be impacted by this study on 91 intracellular budding and remains to be investigated in SARS-CoV-2 (24). Nonetheless, it has 92 been proposed that this virus, and others, acquires a glycan coat sufficient and similar enough to 93 endogenous host protein glycosylation that it serves as a glycan shield, facilitating immune 94 evasion by masking non-self viral peptides with self-glycans (15,20-22). In parallel with their 95 potential masking functions, glycan-dependent epitopes can elicit specific, even neutralizing, 96 antibody responses, as has been described for HIV-1 ((15, 25-29),97 https://www.biorxiv.org/content/10.1101/2020.06.30.178897v1). Thus, understanding the 98 glycosylation of the viral Spike trimer is fundamental for the development of efficacious vaccines, 99 neutralizing antibodies, and therapeutic inhibitors of infection.

100 ACE2 is an integral membrane metalloproteinase that regulates the renin-angiotensin system 101 (30). Both SARS-CoV-1 and SARS-CoV-2 have co-opted ACE2 to function as the receptor by 102 which these viruses attach and fuse with host cells (13,14). ACE2 is cleavable by ADAM 103 proteases at the cell surface (31), resulting in the shedding of a soluble ectodomain which can be 104 detected in apical secretions of various epithelial layers (gastric, airway, etc.) and in serum (32). 105 The N-terminal extracellular domain of ACE2 contains 6 canonical sequons for N-linked 106 glycosylation and several potential O-linked sites. Several nonsynonymous single-nucleotide 107 polymorphisms (SNPs) in the ACE2 gene have been identified in the human population and could 108 potentially alter ACE2 glycosylation and/or affinity of the receptor for the viral Spike protein (33).

Given that glycosylation can affect the half-life of circulating glycoproteins in addition to modulating the affinity of their interactions with receptors and immune/inflammatory signaling pathways (34,35), understanding the impact of glycosylation of ACE2 with respect to its binding of SARS-CoV-2 Spike glycoprotein is of high importance. The proposed use of soluble extracellular domains of ACE2 as decoy, competitive inhibitors for SARS-CoV-2 infection emphasizes the critical need for understanding the glycosylation profile of ACE2 so that optimally active biologics can be produced (17,18).

116 To accomplish the task of characterizing site-specific glycosylation of the trimer Spike of SARS-117 CoV-2 and the host receptor ACE2, we began by expressing and purifying a stabilized, soluble 118 trimer Spike glycoprotein mimetic immunogen (that we define here and forward as S, (36)) and a 119 soluble version of the ACE2 glycoprotein from a human cell line. We utilized multiple mass 120 spectrometry-based approaches, including glycomic and glycoproteomic approaches, to 121 determine occupancy and site-specific heterogeneity of N-linked glycans. Occupancy (i.e. the 122 percent of any given residue being modified by a glycan) is an important consideration when 123 developing neutralizing antibodies against a glycan-dependent epitope. We also identified sites 124 of O-linked glycosylation and the heterogeneity of the O-linked glycans on S and ACE2. We 125 leveraged this rich dataset, along with existing 3D-structures of both glycoproteins, to generate 126 static and molecular dynamics models of S alone, and in complex with the glycosylated, soluble 127 ACE 2 receptor. By combining bioinformatic characterization of viral evolution and variants of the 128 Spike and ACE2 with molecular dynamics simulations of the glycosylated Spike-ACE2 interaction, 129 we identified important roles for glycans in multiple processes, including receptor-viral binding 130 and glycan-shielding of the Spike. Our rich characterization of the recombinant, glycosylated 131 Spike trimer mimetic immunogen of SARS-CoV-2 in complex with the soluble human ACE2 132 receptor provides a detailed platform for guiding rational vaccine, antibody, and inhibitor design.

133

134 **RESULTS**

Expression, Purification, and Characterization of SARS-CoV-2 Spike Glycoprotein Trimer and
 Soluble Human ACE2

137 trimer-stabilized, soluble variant of the SARS-CoV-2 Spike protein (S) that contains 22 Α 138 canonical N-linked glycosylation sequons per protomer and a soluble version of human ACE2 139 that contains 6, lacking the most C-terminal 7th, canonical N-linked glycosylation sequons (Fig. 140 1A) were purified from the media of transfected HEK293 cells and the quaternary structure 141 confirmed by negative EM staining for the S trimer (Fig. 1B) and purity examined by SDS-PAGE 142 Coomassie G-250 stained gels for both (Fig. 1C). In addition, proteolytic digestions followed by 143 proteomic analyses confirmed that the proteins were highly purified (Supplemental Table, Tab 144 12). Finally, the N-terminus of both the mature S and the soluble mature ACE2 were empirically 145 determined via proteolytic digestions and LC-MS/MS analyses. These results confirmed that both 146 the secreted, mature forms of S protein and ACE2 begin with an N-terminal glutamine that has 147 undergone condensation to form pyroglutamine at residue 14 and 18, respectively (Figs. 1D and 148 S1). The N-terminal peptide observed for S also contains a glycan at Asn-0017 (Fig. 1D) and 149 mass spectrometry analysis of non-reducing proteolytic digestions confirmed that Cys-0015 of S 150 is in a disulfide linkage with Cys-0136 (Fig. S2, Supplemental Table, Tab 2). Given that SignalP 151 (37) predicts signal sequence cleavage between Cys-0015 and Val-0016 but we observed 152 cleavage between Ser-0013 and GIn-0014, we examined the possibility that an in-frame upstream 153 Methionine to the proposed start Methionine (Fig. 1A) might be used to initiate translation (Fig. 154 S3). If one examines the predicted signal sequence cleavage using the in-frame Met that is 155 encoded 9 amino acids upstream, SignalP now predicts cleavage between the Ser and Gln that 156 we observed in our studies (Fig. S3). To examine whether this impacted S expression, we 157 expressed constructs that contained or did not contain the upstream 27 nucleotides in a 158 pseudovirus (VSV) system expressing SARS-CoV2 S (Fig. S4) and in our HEK293 system (data 159 not shown). Both expression systems produced a similar amount of S regardless of which 160 expression construct was utilized (Fig. S4). Thus, while the translation initiation start site has still

not been fully defined, allowing for earlier translation in expression construct design did not havea significant impact on the generation of S.

163 Glycomics Informed Glycoproteomics Reveals Site-Specific Microheterogeneity of SARS-CoV-2

164 S Glycosylation

165 We utilized multiple approaches to examine glycosylation of the SARS-CoV-2 S trimer. First, the 166 portfolio of glycans linked to SARS-CoV-2 S trimer immunogen was analyzed following their 167 release from the polypeptide backbone. N-glycans were released from protein by treatment with 168 PNGase F and O-glycans were subsequently released by beta-elimination. Following 169 permethylation to enhance detection sensitivity and structural characterization, released glycans 170 were analyzed by multi-stage mass spectrometry (MSⁿ) (38,39). Mass spectra were processed 171 by GRITS Toolbox and the resulting annotations were validated manually (40). Glycan 172 assignments were grouped by type and by additional structural features for relative quantification 173 of profile characteristics (Fig. 2A, Supplemental Table, Tab 3). This analysis quantified 49 N-174 glycans and revealed that 55% of the total glycan abundance was of the complex type, 17% was 175 of the hybrid type, and 28% was high-mannose. Among the complex and hybrid N-glycans, we 176 observed a high degree of core fucosylation and significant abundance of bisected and LacDiNAc 177 structures. We also observed sulfated N-linked glycans using negative mode MSⁿ analyses 178 (Supplemental Table, Tab 13) though signal intensity was too low in positive ion mode (at least 179 10-fold lower than any of the non-sulfated glycans) for accurate quantification. In addition, we 180 detected 15 O-glycans released from the S trimer (Fig. S5, Supplemental Table, Tab 4).

To determine occupancy of N-linked glycans at each site, we employed a sequential deglycoslyation approach using Endoglycosidase H and PNGase F in the presence of ¹⁸O-H₂O following tryptic digestion of S (28,41). Following LC-MS/MS analyses, the resulting data confirmed that 19 of the canonical sequens had occupancies greater than 95% (**Supplemental Table, Tab 5**). One canonical sequence, N0149, had insufficient spectral counts for quantification by this method but subsequent analyses described below suggested high occupancy. The 2 most C-terminal N-linked sites, N1173 and N1194, had reduced occupancy, 52% and 82% respectively. 188 Reduced occupancy at these sites may reflect hindered en-bloc transfer by the 189 oligosaccharyltransferase (OST) due to primary amino acid sequences at or near the N-linked 190 Alternatively, this may reflect these two sites being post-translationally modified after sequon. 191 release of the protein by the ribosome by a less efficient STT3B-containing OST, either due to 192 activity or initial folding of the polypeptide, as opposed to co-translationally modified by the 193 STT3A-containing OST (42). None of the non-canoncial sequons (3 N-X-C sites and 4 N-G-L/I/V 194 sites, (43)) showed significant occupancy (>5%) except for N0501 that showed moderate (19%) 195 conversion to ¹⁸O-Asp that could be due to deamidation that is facilitated by glycine at the +1 196 position (Supplemental Table, Tab 5, (44)). Further analysis of this site (see below) by direct 197 glycopeptide analyses allowed us to determine that N0501 undergoes deamidation but is not 198 glycosylated. Thus, all, and only the, 22 canonical sequences for N-linked glycosylation (N-X-S/T) 199 are utilized with only N1173 and N1194 demonstrating occupancies below 95%.

200 Next, we applied 3 different proteolytic digestion strategies to the SARS-CoV-2 S immunogen to 201 maximize glycopeptide coverage by subsequent LC-MS/MS analyses. Extended gradient 202 nanoflow reverse-phase LC-MS/MS was carried out on a ThermoFisher Lumos™ Tribrid™ 203 instrument using Step-HCD fragmentation on each of the samples (see STAR methods for details, 204 (25,26,28,41,45)). Following data analyses using pGlyco 2.2.2 (46), Byonic (47), and manual 205 validation of glycan compositions against our released glycomics findings (Fig. 2A, 206 Supplemental Table, Tab 3 and 13), we were able to determine the microheterogeneity at each 207 of the 22 canonical sites (Fig. 2B-2E, Supplemental Table, Tab 6). Notably, none of the non-208 canonical consensus sequences, including N0501, displayed any quantifiable glycans. The N-209 glycosites N0074 (Fig. 2B) and N0149 (Fig. 2C) are highly processed and display a typical 210 mammalian N-glycan profile. N0149 is, however, modified with several hybrid N-glycan structures 211 while N0074 is not. N0234 (Fig. 2D) and N0801 (Fig. 2E) have N-glycan profiles more similar to 212 those found on other viruses such as HIV (15) that are dominated by high-mannose structures. 213 N0234 (Fig. 2D) displays an abundance of Man7 - Man9 high-mannose structures suggesting 214 stalled processing by early acting ER and cis-Golgi mannosidases. In contrast, N0801 (Fig. 2E)

215 is processed more efficiently to Man5 high-mannose and hybrid structures suggesting that access 216 to the glycan at this site by MGAT1 and α -Mannosidase II is hindered. In general, for all 22 sites 217 (Fig. 2B-2E, Supplemental Table, Tab 6), we observed under processing of complex glycan 218 antennae (i.e. under-galactosylation and under-sialylation) and a high degree of core fucosylation 219 in agreement with released glycan analyses (Fig. 2A, Supplemental Table, Tab 3). We also 220 observed a small percent of sulfated N-linked glycans at several sites (Supplemental Table, Tab 221 6 and 8). Based on the assignments and the spectral counts for each topology, we were able to 222 determine the percent of total N-linked glycan types (high-mannose, hybrid, or complex) present 223 at each site (Figure 3, Supplemental Table, Tab 7). Notably, 3 of the sites (N0234, N0709, and 224 N0717) displayed more than 50% high-mannose glycans while 11 other sites (N0017, N0074, 225 N0149, N0165, N0282, N0331, N0657, N1134, N1158, N1173, and N1194) were more than 90% 226 complex when occupied. The other 8 sites were distributed between these 2 extremes. Notably, 227 only 1 site (N0717 at 45%), which also had greater than 50% high-mannose (55%), had greater 228 than 33% hybrid structures. To further evaluate the heterogeneity, we grouped all the topologies 229 into the 20 classes recently described by the Crispin laboratory with adding 2 categories (sulfated 230 and unoccupied) that we refer to here as the Oxford classification (Supplemental Table, Tab 8, 231 (19)). Among other features observed, this classification allowed us to observe that while most 232 sites with high mannose structures were dominated by the Man5GlcNAc2 structure, N0234 and 233 N0717 were dominated by the higher Man structures of Man8GlcNAc2 and Man7GlcNAc2. 234 respectively (Fig. S7, Supplemental Table, Tab 8). Limited processing at N0234 is in agreement 235 with a recent report suggesting that high mannose structures at this site help to stabilize the 236 (www.biorxiv.org/content/10.1101/2020.06.11.146522v1). receptor-binding domain of S 237 Furthermore, applying the Oxford classifications to our dataset clearly demonstrates that the 3 238 most C-terminal sites (N1158, N1173, and N1194), dominated by complex type glycans, were 239 more often further processed (i.e. multiple antennae) and elaborated (i.e. galactosylation and 240 sialylation) than other sites (Supplemental Table, Tab 8).

We also analyzed our generated mass spectrometry data for the presence of O-linked glycans based on our glycomic findings (**Fig. S5**, **Supplemental Table**, **Tab 4**) and a recent manuscript suggesting significant levels of O-glycosylation of S1 and S2 when expressed independently (23). We were able to confirm sites of O-glycan modification with microheterogeneity observed for the vast majority of these sites (**Supplemental Table**, **Tab 9**). However, occupancy at each site, determined by spectral counts, was observed to be very low (below 4%) except for Thr0323 that had a modestly higher but still low 11% occupancy (**Fig. S6, Supplemental Table, Tab 10**).

248 3D Structural Modeling of Glycosylated SARS-CoV-2 Trimer Immunogen Enables Predictions of

249 Epitope Accessibility and Other Key Features

250 A 3D structure of the S trimer was generated using a homology model of the S trimer described 251 previously (based on PDB code 6VSB, (48)). Onto this 3D structure, we installed explicitly defined 252 glycans at each glycosylated sequon based on one of three separate sets of criteria, thereby 253 generating three different glycoform models for comparison that we denote as "Abundance." 254 "Oxford Class," and "Processed" models (see Methods and Supplemental Table, Tab 1). These 255 criteria were chosen in order to generate glycoform models that represent reasonable 256 expectations for glycosylation microheterogeneity and integrate cross-validating glycomic and 257 glycoproteomic characterization of S and ACE2.

258 The three glycoform models were subjected to multiple all atom MD simulations with explicit 259 water. Information from analyses of these structures is presented in Figure 4A along with the 260 sequence of the SARS-CoV-2 S protomer. We also determined variants in S that are emerging in 261 the virus that have been sequenced to date (Supplemental Table, Tab 11). The inter-residue 262 distances were measured between the most α -carbon-distal atoms of the N-glycan sites and 263 Spike glycoprotein population variant sites in 3D space (Figure 4B). Notable from this analysis, 264 there are several variants that don't ablate the N-linked sequon, but that are sufficiently close in 265 3-dimensional space to N-glycosites, such as D138H, H655Y, S939F, and L1203F, to warrant 266 further investigation.

267 The percentage of simulation time that each S protein residue is accessible to a probe that 268 approximates the size of an antibody variable domain was calculated for a model of the S trimer 269 using the Abundance glycoforms (Supplemental Table, Tab 1, (49)). The predicted antibody 270 accessibility is visualized across the sequence, as well as mapped onto the 3D surface, via color 271 shading (Figure 4A, 4C, Supplemental Table, Tab 13, and Supplemental Movie A). 272 Additionally, the Oxford Class glycoforms model (Supplemental Table, Tab 1), which is arguably 273 the most encompassing means for representing glycan microheterogeneity since it captures 274 abundant structural topologies (Supplemental Table, Tab 8), is shown with the sequence variant 275 information (Figure 4D, Supplemental Table, Tab 11). A substantial number of these variants 276 occur (directly by comparison to Figure 4A or visually by comparison to Figure 4C) in regions of 277 high calculated epitope accessibility (e.g. N74K, T76I, R78M, D138H, H146Y, S151I, D253G, 278 V483A, etc., Supplemental Table, Tab 14) suggesting potential selective pressure to avoid host 279 immune response. Also, it is interesting to note that 3 of the emerging variants would eliminate 280 N-linked sequons in S; N74K and T76I would eliminate N-glycosylation of N74 (found in the insert 281 variable region 1 of CoV-2 S compared to CoV-1 S), and S151I eliminates N-glycosylation of 282 N149 (found in the insert variable region 2) (Fig. 4A, S7, Supplemental Table, Tab 11). Lastly, 283 the SARS-CoV-2 S Processed glycoform model is shown (Supplemental Table, Tab 1), along 284 with marking amino acid T0323 that has a modest (11% occupancy, Fig. S6, Supplemental 285 Table, Tab 10) amount of O-glycosylation to represent the most heavily glycosylated form of S 286 (Figure 4E).

287 Glycomics Informed Glycoproteomics Reveals Complex N-linked Glycosylation of ACE2

We also analyzed ACE2 glycosylation utilizing the same glycomic and glycoproteomic approaches described for S protein. Glycomic analyses of released N-linked glycans (**Fig. 5A**, **Supplemental Table, Tab 3**) revealed that the majority of glycans on ACE2 are complex with limited high-mannose and hybrid glycans and we were unable to detect sulfated N-linked glycans. Glycoproteomic analyses revealed that occupancy was high (>75%) at all 6 sites and significant microheterogeneity dominated by complex N-glycans was observed for each site (**Fig. 5B-5G**, Supplemental Table, Tabs 5-8). We also observed, consistent with the O-glycomics (Fig. S5,
Supplemental Table, Tab 4), that Ser 155 and several S/T residues at the C-terminus of ACE2
outside of the peptidase domain were O-glycosylated but stoichiometry was extremely low (less
than 2%, Supplemental Table, Tab 9 and 10).

298 3D Structural Modeling of Glycosylated, Soluble, ACE2 Highlighting Glycosylation and Variants. 299 We integrated our glycomics, glycoproteomics, and population variant analyses results with a 3D 300 model of Ace 2 (based on PDB code 6M0J (50), see methods for details) to generate two versions 301 of the soluble glycosylated ACE2 for visualization and molecular dynamics simulations. We 302 visualized the ACE2 glycoprotein with the Abundance glycoform model simulated at each site as 303 well as highlighting the naturally occurring variants observed in the human population (Fig. 6A, 304 Supplemental Movie B, Supplemental Table, Tab 11). Note, that the Abundance glycoform 305 model and the Oxford Class glycoform model for ACE2 are identical (Supplemental Table, Tabs 306 1 and 8). Notably, one site of N-linked glycosylation (N546) is predicted to not be present in 3 307 out of 10,000 humans based on naturally occurring variation in the human population 308 (Supplemental Table, Tab 11). We also modeled ACE2 using the Processed glycoform model 309 (Fig. 6B). In both models, the interaction domain with S is defined (Fig. 6A-B, Supplemental 310 Movie B).

311 Molecular Dynamics Simulation of the Glycosylated Trimer Spike of SARS-CoV-2 in Complex

312 with Glycosylated, Soluble, Human Ace 2 Reveals Protein and Glycan Interactions

313 Molecular dynamics simulations were performed to examine the co-complex (generated from a 314 crystal structure of the ACE2-RBD co-complex, PDB code 6M0J, (50)) of glycosylated S with 315 glycosylated ACE2 with the 3 different glycoforms models (Abundance, Oxford Class, and 316 Processed, Supplemental Table, Tab 1, Supplemental Simulations 1-3). Information from 317 these analyses is laid out along the primary structure (sequence) of the SARS-CoV-2 S protomer 318 and ACE2 highlighting regions of glycan-protein interaction observed in the MD simulations 319 (Supplemental Table, Tab 14, Supplemental Simulations 1-3). Interestingly, two glycans on 320 ACE2 (at N090 and N322), that are highlighted in Figure 7A and shown in a more close-up view 321 in Figure 7B, are predicted to form interactions with the S protein (Supplemental Table, Tab 15). 322 The N322 glycan interaction with the S trimer is outside of the receptor binding domain, and the 323 interaction is observed across multiple simulations and throughout each simulation (Fig. 7A-B, 324 Supplemental Simulations 1-3). The ACE2 glycan at N090 is close enough to the S trimer 325 surface to repeatedly form interactions, however the glycan arms interact with multiple regions of 326 the surface over the course of the simulations, reflecting the relatively high degree of glycan 327 dynamics (Fig. 7A-B, Supplemental Movie C). Inter-molecule glycan-glycan interactions are 328 also observed repeatedly between the glycan at N546 of ACE2 and those in the S protein at 329 residues N0074 and N0165 (Fig. 7D, Supplemental Table, Tab 16). Finally, a full view of the 330 ACE2-S complex with Oxford class glycoforms on both proteins illustrates the extensive 331 glycosylation at the interface of the complex (Fig. 7C, Supplemental Movie D).

332

333 DISCUSSION

We have defined the glycomics-informed, site-specific microheterogeneity of 22 sites of N-linked glycosylation per monomer on a SARS-CoV-2 trimer and the 6 sites of N-linked glycosylation on a soluble version of its human ACE2 receptor using a combination of mass spectrometry approaches coupled with evolutionary and variant sequence analyses to provide a detailed understanding of the glycosylation states of these glycoproteins (**Figs. 1-6**). Our results suggest essential roles for glycosylation in mediating receptor binding, antigenic shielding, and potentially the evolution/divergence of these glycoproteins.

The highly glycosylated SARS-CoV-2 Spike protein, unlike several other viral proteins including HIV-1 (15) but in agreement with another recent report (19), presents significantly more processing of N-glycans towards complex glycosylation, suggesting that steric hindrance to processing enzymes is not a major factor at most sites (**Figs. 2-3**). However, the N-glycans still provide considerable shielding of the peptide backbone (**Fig. 4**). Our glycomics-guided glycoproteomic data is in general in strong agreement with the trimer immunogen data recently published by Crispin (19) though we also observed sulfated N-linked glycans, were able to

348 differentiate branching, bisected, and diLacNAc containing structures by glycomics, and observed 349 less occupancy on the 2 most C-terminal N-linked sites using a different approach. Our detection 350 of sulfated N-linked glycans at multiple sites on S is in agreement with a recent manuscript re-351 analyzing the Crispin data (https://www.biorxiv.org/content/10.1101/2020.05.31.125302v1). 352 Sulfated N-linked glycans could potentially play key roles in immune regulation and receptor 353 binding as in other viruses (51). This result is especially significant in that sulfated N-glycans 354 were not observed when we performed glycomics on ACE2. At each individual site, the glycans 355 we observed on our immunogen appear to be slightly more processed but the overlap between 356 our analysis and the Crispin's group results (19) at each site in terms of major features are nearly 357 superimposable. This agreement differs substantially when comparing our and Crispin's data (19) 358 to that of the Azadi group (23) that analyzed S1 and S2 that had been expressed individually. 359 When expressed as 2 separate polypeptides and not purified for trimers, several unoccupied 360 sites of N-linked glycosylation were observed and processing at several sites was significantly 361 different (23) than we and others (19) observed. Although O-glycosylation has recently been 362 reported for individually-expressed S1 and S2 domains of the Spike glycoprotein (23), in trimeric 363 form the level of O-glycosylation is extremely low, with the highest level of occupancy we observed 364 being 11% at T0323 (Fig. 4E). The low level of O-linked occupancy we observed is in agreement 365 with Crispin's analysis of a Spike Trimer immunogen (19) but differs significantly from Azadi's 366 analyses of individually expressed S1 and S2 (23). Thus, the context in which the Spike protein 367 is expressed and purified before analyses significantly alters the glycosylation of the protomer 368 that is reminiscent of previous studies looking at expression of the HIV-1 envelope Spike (15.52). 369 The soluble ACE2 protein examined here contains 6 highly utilized sites of N-linked glycosylation 370 dominated by complex type N-linked glycans (Fig. 5). O-glycans were also present on this 371 glycoprotein but at very low levels of occupancy at all sites (<2%).

Our glycomics-informed glycoproteomics allowed us to assign defined sets of glycans to specific glycosylation sites on 3D-structures of S and ACE2 glycoproteins based on experimental evidence (**Figs. 4, 6**). Similar to almost all glycoproteins, microheterogeneity is evident at most

375 glycosylation sites of S and ACE2; each glycosylation site can be modified with one of several 376 glycan structures, generating site-specific glycosylation portfolios. For modeling purposes, 377 however, explicit structures must be placed at each glycosylation site. In order to capture the 378 impact of microheterogenity on S and ACE2 molecular dynamics we chose to generate 379 glycoforms for modeling that represented reasonable portfolios of glycan types. Usina 3 380 glycoform models for S (Abundance, Oxford Class, and Processed) and 2 models for ACE2 381 (Abundance, which was equivalent to Oxford Class, and Processed), we generated 3 molecular 382 dynamics simulations of the co-complexes of these 2 glycoproteins (Fig. 7 and Supplemental 383 Simulations 1-3). The observed interactions over time allowed us to evaluate glycan-protein 384 contacts between the 2 proteins as well as examine potential glycan-glycan interactions (Fig. 7). 385 We observed glycan-mediated interactions between the S trimer and glycans at N090, N322 and 386 N546 of ACE2. Thus, variations in glycan occupancy or processing at these sites, could alter the 387 affinity of the SARS-CoV-2 – ACE2 interaction and modulate infectivity. It is well established that 388 glycosylation states vary depending on tissue and cell type as well as in the case of humans, on 389 age (53), underlying disease (54,55) and ethnicity (56). Thus glycosylation portfolios may in part 390 be responsible for tissue tropism and individual susceptibility to infection. The importance of 391 glycosylation for S binding to ACE2 is even more emphatically demonstrated by the direct glycan-392 glycan interactions observed (Fig. 7) between S glycans (at N0074 and N0165) and an ACE2 393 receptor glycan (at N546), adding an additional layer of complexity for interpreting the impact of 394 glycosylation on individual susceptibility.

Several emerging variants of the virus appear to be altering N-linked glycosylation occupancy by disrupting N-linked sequons. Interestingly, the 2 N-linked sequons in SARS-CoV-2 S directly impacted by variants, N0074 and N0149, are in divergent insert regions 1 and 2, respectively, of SARS-CoV-2 S compared to SARS-CoV-1 S (**Fig. 4A**). The N0074, in particular, is one of the S glycans that interact directly with ACE2 glycan (at N546, **Fig. 7**), suggesting that glycan-glycan interactions may contribute to the unique infectivity differences between SARS-CoV-2 and SARS-CoV-1. These sequen variants will also be important to examine in terms of glycan shielding that 402 could influence immunogenicity and efficacy of neutralizing antibodies, as well as interactions with 403 the host cell receptor ACE2. Naturally-occurring amino acid-changing SNPs in the ACE2 gene 404 generate a number of variants including 1 variant, with a frequency of 3 in 10,000 humans, that 405 eliminates a site of N-linked glycosylation at N546 (Fig. 6). Understanding the impact of ACE2 406 variants on glycosylation and more importantly on S binding, especially for N546S which impacts 407 the glycan-glycan interaction between S and ACE2 (Fig. 7), should be prioritized in light of efforts 408 to develop ACE2 as a potential decoy therapeutic. Intelligent manipulation of ACE2 glycosylation 409 may lead to more potent biologics capable of acting as better competitive inhibitors of S binding. 410 The data presented here, and related similar recent findings (19,57,58), provide a framework to 411 facilitate the production of immunogens, vaccines, antibodies, and inhibitors as well as providing 412 additional information regarding mechanisms by which glycan microheterogeneity is achieved. 413 However, considerable efforts still remain in order to fully understand the role of glycans in SARS-414 CoV-2 infection and pathogenicity. While HEK-expressed S and ACE2 provide a useful window 415 for understanding human glycosylation of these proteins, glycoproteomic characterization 416 following expression in cell lines of more direct relevance to disease and target tissue is sorely 417 needed. While site occupancy may change depending on presentation and cell type (59), 418 processing of N-linked glycans will almost certainly be altered in a cell-type dependent fashion. 419 Thus, analyses of the Spike trimer extracted from pseudoviruses, virion-like particles, and 420 ultimately from infectious SARS-CoV-2 virions harvested from airway cells or patients will provide 421 the most accurate view of how trimer immunogens reflect the true glycosylation pattern of the 422 virus. Detailed analyses of the impact of emerging variants in S and natural and designed-for-423 biologics variants of ACE2 on glycosylation and binding properties are important next steps for 424 developing therapeutics. Finally, it will be important to monitor the slow evolution of the virus to 425 determine if existing sites of glycosylation are lost or new sites emerge with selective pressure 426 that might alter the efficacy of vaccines, neutralizing antibodies, and/or inhibitors.

427

428 ACKNOWLEDGEMENTS

429 The authors would like to thank Protein Metrics for providing licenses for their software used here 430 and the developers of pGlyco for productive discussions regarding their software. We would also 431 like to thank Galit Alter of the Ragon Institute for facilitating this collaborative effort. This effort 432 was facilitated by the ThermoFisher Scientific appointed Center of Excellence in Glycoproteomics 433 at the Complex Carbohydrate Research Center at the University of Georgia (co-directed by MT 434 and LW). This research is supported in part by R35GM119850 (NEL), NNF10CC1016517 (NEL), 435 R01AI139238 (MAB), R01AI147884-01A1S1 (BC), Massachusetts Consortium on Pathogen 436 Readiness (BC), U01CA207824 (R.J.W), P41GM103390 (R.J.W.), P41GM103490 (MT and LW), 437 U01GM125267 (MT), and R01GM130915 (LW). The content is solely the responsibility of the 438 authors and does not necessarily represent the official views of the National Institutes of Health.

439

440 AUTHOR CONTRIBUTIONS

- 441 Conceptualization: M.T., B.C., R.J.W. and L.W.; Methodology, Software, Validation, Formal
- 442 Analysis, Investigation, Resources, and Data Curation: P.Z., J.L.P., O.C.G., Y.C., T.X., K.E.R.,
- 443 K.A., B.P.K., R.B., D.H.B., M.A.B., N.E.L., M.T., B.C., R.J.W., and L.W.; Writing-Original Draft:
- 444 P.Z., J.L.P., and L.W.; Writing-Review & Editing: All authors; Visualization: P.Z., J.L.P., O.C.G,
- 445 Y.C., M.T., B.C., R.J.W., and L.W.; Supervision, Project Administration, and Funding Acquisition:
- 446 D.H.B., M.A.B., N.E.L., M.T., B.C., R.J.W., and L.W..
- 447

448 **DECLARATION OF INTERESTS**

- 449 The authors declare no competing interests.
- 450

451 **FIGURE LEGENDS**

452

Figure 1. Expression and Characterization of SARS-CoV-2 Spike Glycoprotein Trimer
Immunogen and Soluble Human ACE2. A) Sequences of SARS-CoV-2 S immunogen and
soluble human ACE2. The N-terminal pyroglutamines for both mature protein monomers are

456 bolded, underlined, and shown in green. The canonical N-linked glycosylation sequons are 457 bolded, underlined, and shown in red. Negative stain electron microscopy of the purified trimer 458 (B) and Coomassie G-250 stained reducing SDS-PAGE gels (C) confirmed purity of the SARS-459 CoV-2 S protein trimer and of the soluble human ACE2. MWM = molecular weight markers. D) 460 A representative Step-HCD fragmentation spectrum from mass spectrometry analysis of a tryptic 461 digest of S annotated manually based on search results from pGlyco 2.2. This spectrum defines 462 the N-terminus of the mature protein monomer as (pyro-)glutamine 0014. A representative N-463 glycan consistent with this annotation and our glycomics data (Fig. 2) is overlaid using the Symbol 464 Nomenclature For Glycans (SNFG) code. This complex glycan occurs at N0017. Note, that as 465 expected, the cysteine is carbamidomethylated and the mass accuracy of the assigned peptide 466 is 0.98 ppm. On the sequence of the N-terminal peptide and in the spectrum, the assigned b (blue) 467 and y (red) ions are shown. In the spectrum, purple highlights glycan oxonium ions and green 468 marks intact peptide fragment ions with various partial glycan sequences still attached. Note that 469 the green-labeled ions allow for limited topology to be extracted including defining that the fucose 470 is on the core and not the antennae of the glycopeptide.

471

472 Figure 2. Glycomics Informed Glycoproteomics Reveals Substantial Site-Specific 473 Microheterogeneity of N-linked Glycosylation on SARS-CoV-2 S. A) Glycans released from 474 SARS-CoV-2 S protein trimer immunogen were permethylated and analyzed by MSn. Structures 475 were assigned, grouped by type and structural features, and prevalence was determined based 476 on ion current. The pie chart shows basic division by broad N-glycan type. The bar graph provides 477 additional detail about the glycans detected. The most abundant structure with a unique 478 categorization by glycomics for each N-glycan type in the pie chart, or above each feature 479 category in the bar graph, is indicated. B - E Glycopeptides were prepared from SARS-CoV-2 480 S protein trimer immunogen using multiple combinations of proteases, analyzed by LC-MSn, and 481 the resulting data was searched using several different software packages. Four representative 482 sites of N-linked glycosylation with specific features of interest were chosen and are presented

483 here. N0074 (B) and N0149 (C) are shown that occur in variable insert regions of S compared to 484 SARS-CoV and other related coronaviruses, and there are emerging variants of SARS-CoV-2 485 that disrupt these two sites of glycosylation in S. N0234 (D) contains the most high-mannose N-486 linked glycans. N0801 (D) is an example of glycosylation in the S2 region of the immunogen and 487 displays a high degree of hybrid glycosylation compared to other sites. The abundance of each 488 composition is graphed in terms of assigned spectral counts. Representative glycans (as 489 determined by glycomics analysis) for several abundant compositions are shown in SNFG format. 490 The abbreviations used here and throughout the manuscript are N for HexNAc, H for Hexose, F 491 for Fucose, A for Neu5Ac, and S for Sulfation. Note that the graphs for the other 18 sites and 492 other graphs grouping the microheterogeneity observed by other properties are presented in 493 Supplemental Information.

494

Figure 3. SARS-CoV-2 S Immunogen N-glycan Sites are Predominantly Modified by Complex N-glycans. N-glycan topologies were assigned to all 22 sites of the S protomer and the spectral counts for each of the 3 types of N-glycans (high-mannose, hybrid, and complex) as well as the unoccupied peptide spectral match counts at each site were summed and visualized as pie charts. Note that only N1173 and N1194 show an appreciable amount of the unoccupied amino acid.

501

502 Figure 4. 3D Structural Modeling of Glycosylated SARS-CoV-2 Spike Trimer Immunogen 503 Reveals Predictions for Antigen Accessibility and Other Key Features. Results from 504 glycomics and glycoproteomics experiments were combined with results from bioinformatics 505 analyses and used to model several versions of glycosylated SARS-CoV-2 S trimer immunogen. 506 A) Sequence of the SARS-CoV-2 S immunogen displaying computed antigen accessibility and 507 other information. Antigen accessibility is indicated by red shading across the amino acid 508 B) Emerging variants confirmed by independent sequencing experiments were sequence. 509 analyzed based on the 3D structure of SARS-CoV-2 S to generate a proximity chart to the

510 determined N-linked glycosylation sites. C) SARS-CoV-2 S trimer immunogen model from MD 511 simulation displaying abundance glycoforms and antigen accessibility shaded in red for most 512 accessible, white for partial, and black for inaccessible (see Supplemental movie A). D) SARS-513 CoV-2 S trimer immunogen model from MD simulation displaying oxford class glycoforms and 514 sequence variants. * indicates not visible while the box represents 3 amino acid variants that are 515 clustered together in 3D space. E) SARS-CoV-2 S trimer immunogen model from MD simulation 516 displaying processed glycoforms plus shading of Thr-323 that has O-glycoslyation at low 517 stoichiometry in yellow.

518

519 Figure 5: Glycomics Informed Glycoproteomics of Soluble Human ACE2 Reveals High 520 Occupancy, Complex N-linked Glycosylation. A) Glycans released from soluble, purified 521 ACE2 were permethylated and analyzed by MSn. Structures were assigned, grouped by type and 522 structural features, and prevalence was determined based on ion current. The pie chart shows 523 basic division by broad N-glycan type. The bar graph provides additional detail about the glycans 524 detected. The most abundant structure with a unique categorization by glycomics for each N-525 glycan type in the pie chart, or above each feature category in the bar graph, is indicated. B - G) 526 Glycopeptides were prepared from soluble human ACE2 using multiple combinations of 527 proteases, analyzed by LC-MSn, and the resulting data was searched using several different 528 software packages. All six sites of N-linked glycosylation are presented here. Displayed in the bar 529 graphs are the individual compositions observed graphed in terms of assigned spectral counts. 530 Representative glycans (as determined by glycomics analysis) for several abundant compositions 531 are shown in SNFG format. The abbreviations used here and throughout the manuscript are N 532 for HexNAc, H for Hexose, F for Fucose, and A for Neu5Ac. The pie chart (analogous to Figure 533 3 for SARS-CoV-2 S) for each site is displayed in the upper corner of each panel. B) N053. C) 534 N090. D) N103. E) N322. F) N432. G) N546, a site that does not exist in 3 in 10,000 people. 535

Figure 6: 3D Structural Modeling of Glycosylated Soluble Human ACE2. Results from glycomics and glycoproteomics experiments were combined with results from bioinformatics analyses and used to model several versions of glycosylated soluble human ACE2. A) Soluble human ACE2 model from MD simulations displaying abundance glycoforms, interaction surface with S, and sequence variants. N546 variant is boxed that would remove N-linked glycosylation at that site (see **Supplemental movie B**). B) Soluble human ACE2 model from MD simulations displaying processed glycoforms and interaction surface with S.

543

544 Figure 7: Interactions of Glycosylated Soluble Human ACE2 and Glycosylated SARS-CoV-545 2 S Trimer Immunogen Revealed By 3D-Structural Modeling and Molecular Dynamics 546 Simulations. A) Molecular dynamics simulation of glycosylated soluble human ACE2 and 547 glycosylated SARS-CoV-2 S trimer immunogen interaction (see Supplemental simulations 1-548 3). ACE2 (top) is colored red with glycans in pink while S is colored white with glycans in dark 549 grey. Highlighted are ACE2 glycans that interacts with S that are zoomed in on to the right. B) 550 Zoom in of ACE2-S interface highlighting ACE2 glycan interactions using 3D-SNFG icons (60) 551 with S protein (pink) as well as ACE2-S glycan-glycan interactions. C) Zoom in of dynamics 552 trajectory of glycans at the interface of soluble human ACE2 and S (see Supplemental movies 553 C and D).

554

555 STAR METHODS

556 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER		
Chemicals, Peptides, and Recombinant Proteins				
SARS-CoV-2 S protein	This Study	N/A		
Human ACE2 protein	This Study	N/A		
2x Laemmli sample buffer	Bio-Rad	Cat#161-0737		
Invitrogen NuPAGE 4 to 12%, Bis-Tris, Mini Protein Gel	Thermo Fisher Scientific	Cat#NP0321PK2		
Coomassie Brilliant Blue G-250 Dye	Thermo Fisher Scientific	Cat#20279		
Dithiothreitol	Sigma Aldrich	Cat#43815		
lodoacetamide	Sigma Aldrich	Cat#I1149		

Trypsin	Promega	Cat#V5111
Lys-C	Promega	Cat#V1671
Arg-C	Promega	Cat#V1881
Glu-C	Promega	Cat#V1651
Asp-N	Promega	Cat#VA1160
Endoglycosidase H	Promega	Cat#V4871
PNGaseF	Promega	Cat#V4831
Chymotrypsin	Athens Research and	Cat#16-19-030820
	Technology	
Alpha lytic protease	New England BioLabs	Cat#P8113
¹⁸ O water	Cambridge Isotope Laboratories	OLM-782-10-1
O-protease OpeRATOR	Genovis	Cat#G1-OP1-020
Deposited Data		
MS data for site-specific N-linked glycopeptides for	This Study	PXD019937
SARS-Cov-2 S and human ACE2		
MS data for site-specific O-linked glycopeptides for SARS-Cov-2 S and human ACE2	This Study	PXD019940
MS data for deglycosylated N-linked glycopeptides for SARS-Cov-2 S and human ACE2	This Study	PXD019938
MS data for disulfide bond analysis for SARS-Cov-2 S	This Study	PXD019939
MS data for N-linked glycomics deposited at GlycoPost	This Study	GPST000120
MS data for O-linked glycomics deposited at GlycoPost	This Study	GPST000121
Experimental Models: Cell Lines		
293-F Cells	Gibco	Cat#R79007
	Cibco	041#1110001
Experimental Models: Organisms/Strains		
VSV(G)-Pseudoviruses	This Study	
Software and Algorithms		
pGlyco	(43)	v2.2.2
Proteome Discoverer	Thermo Fisher Scientific	v1.4
Byonic	Protein Metrics Inc. (44)	v3.8.13
ProteolQ	Premier Biosoft	v2.7
GRITS Toolbox	http://www.grits- toolbox.org (40)	v1.1
EMBOSS needle	(61)	v6.6.0
Biopython	https://biopython.org/	v1.76
Rpdb	https://rdrr.io/cran/Rpd b/	v2.3
SignalP	http://www.cbs.dtu.dk/ services/SignalP/ (34)	v5.0
		1
LibreOFFICE Writer	The Document Foundation	V6.4.4.2

GNOme	https://github.com/glyg en-glycan- data/GNOme/blob/ma ster/README.md	V1.5.5
GlyTouCan	https://glytoucan.org	V3.1.0
Inkscape	Inkscape Developers	V1.0

557

558 LEAD CONTACT

- 559 Further information and requests for resources and reagents should be directed to and will be
- 560 fulfilled by the Lead Contact, Peng Zhao (pengzhao@uga.edu) and/or Lance Wells
- 561 (<u>lwells@ccrc.uga.edu</u>).
- 562

563 **METHOD DETAILS**

564 Expression, Purification, and Characterization of SARS-CoV-2 S and Human ACE2

565 **Proteins**

566 To express a stabilized ectodomain of Spike protein, a synthetic gene encoding residues

567 1-1208 of SARS-CoV-2 Spike with the furin cleavage site (residues 682–685) replaced by a

568 "GGSG" sequence, proline substitutions at residues 986 and 987, and a foldon trimerization

569 motif followed by a C-terminal 6xHisTag was created and cloned into the mammalian

570 expression vector pCMV-IRES-puro (Codex BioSolutions, Inc, Gaithersburg, MD). The

571 expression construct was transiently transfected in HEK 293F cells using polyethylenimine

572 (Polysciences, Inc, Warrington, PA). Protein was purified from cell supernatants using Ni-NTA

573 resin (Qiagen, Germany), the eluted fractions containing S protein were pooled, concentrated,

and further purified by gel filtration chromatography on a Superose 6 column (GE Healthcare).

575 Negative stain electron microscopy (EM) analysis was performed as described (62). Briefly,

576 analysis was performed at room temperature with a magnification of 52,000x and a defocus

577 value of 1.5 μm following low-dose procedures, using a Philips Tecnai F20 electron microscope

578 (Thermo Fisher Scientific) equipped with a Gatan US4000 CCD camera and operated at voltage

579 of 200 kV. The DNA fragment encoding human ACE2 (1-615) with a 6xHis tag at C terminus

580 was synthesized by Genscript and cloned to the vector pCMV-IRES-puro. The expression

581 construct was transfected in HEK293F cells using polyethylenimine. The medium was discarded

and replaced with FreeStyle 293 medium after 6-8 hours. After incubation in 37 °C with 5.5%

- 583 CO2 for 5 days, the supernatant was collected and loaded to Ni-NTA resin for purification. The
- elution was concentrated and further purified by a Superdex 200 column.

585 In-Gel Analysis of SARS-CoV-2 S and Human ACE2 Proteins

586 A 3.5-µg aliquot of SARS-CoV-2 S protein as well as a 2-µg aliquot of human ACE2 were

587 combined with Laemmli sample buffer, analyzed on a 4-12% Invitrogen NuPage Bis-Tris gel

using the MES pH 6.5 running buffer, and stained with Coomassie Brilliant Blue G-250.

589 Analysis of N-linked and O-linked Glycans Released from SARS-Cov-2 S and Human

590 ACE2 Proteins

591 Aliquots of approximately 25-50 µg of S or ACE2 protein were processed for glycan analysis as 592 previously described (38,39). For N-linked glycan analysis, the proteins were digested with 593 trypsin. Following trypsinization, glycopeptides were enriched by C18 Sep-Pak and subjected to 594 PNGaseF digestion to release N-linked glycans. Following PNGaseF digestion, released 595 glycans were separated from residual glycosylated peptides bearing O-linked glycans by C18 596 Sep-Pak. O-glycosylated peptides were eluted from the Sep-Pak and subjected to reductive β -597 elimination to release the O-glycans. Another 25-50 µg aliguot of each protein was denatured 598 with SDS and digested with PNGaseF to remove N-linked glycans. The de-N-glycosylated, 599 intact protein was precipitated with cold ethanol and then subjected to reductive β -elimination to 600 release O-glycans. The profiles of O-glycans released from peptides or from intact protein were 601 found to be comparable. N- and O-linked glycans released from glycoproteins were 602 permethylated with methyliodide according to the method of Anumula and Taylor prior to MS

- analysis (63). Glycan structural analysis was performed using an LTQ-Orbitrap instrument
- 604 (Orbitrap Discovery, ThermoFisher). Detection and relative quantification of the prevalence of

605 individual glycans was accomplished using the total ion mapping (TIM) and neutral loss scan 606 (NL scan) functionality of the Xcalibur software package version 2.0 (Thermo Fisher Scientific) 607 as previously described (38,39). Mass accuracy and detector response was tuned with a 608 permethylated oligosaccharide standard in positive ion mode. For fragmentation by collision-609 induced dissociation (CID in MS² and MSn), normalized collision energy of 45% was applied. 610 Most permethylated glycans were identified as singly or doubly charged, sodiated species in 611 positive mode. Sulfated N-glycans were detected as singly or doubly charged, deprotonated 612 species in negative ion mode. Peaks for all charge states were deconvoluted by the charge 613 state and summed for quantification. All spectra were manually interpreted and annotated. The 614 explicit identities of individual monosaccharide residues have been assigned based on known 615 human biosynthetic pathways. Graphical representations of monosaccharide residues are 616 consistent with the Symbol Nomenclature for Glycans (SNFG), which has been broadly adopted 617 by the glycomics community (64). The MS-based glycomics data generated in these analyses 618 and the associated annotations are presented in accordance with the MIRAGE standards and 619 the Athens Guidelines (65). Data annotation and assignment of glycan accession identifiers 620 were facilitated by GRITS Toolbox, GlyTouCan, GNOme, and GlyGen (40,66-68). 621 Analysis of Disulfide Bonds for SARS-Cov-2 S Protein by LC-MS 622 Two 10-µg aliguots of SARS-CoV-2 S protein were denatured by incubating with 20% 623 acetonitrile at room temperature and alkylated by 13.75 mM of iodoacetamide at room 624 temperature in dark. The two aliquots of proteins were then digested respectively using alpha 625 lytic protease, or a combination of trypsin, Lys-C and Glu-C. Following digestion, the proteins 626 were deglycosylated by PNGaseF treatment. The resulting peptides were separated on an 627 Acclaim PepMap RSLC C18 column (75 µm x 15 cm) and eluted into the nano-electrospray ion 628 source of an Orbitrap Fusion[™] Lumos[™] Tribrid[™] mass spectrometer at a flow rate of 200

- 629 nL/min. The elution gradient consists of 1-40% acetonitrile in 0.1% formic acid over 370 minutes
- 630 followed by 10 minutes of 80% acetonitrile in 0.1% formic acid. The spray voltage was set to 2.2

kV and the temperature of the heated capillary was set to 280 °C. Full MS scans were acquired
from m/z 200 to 2000 at 60k resolution, and MS/MS scans following electron transfer
dissociation (ETD) were collected in the Orbitrap at 15k resolution. The raw spectra were
analyzed by Byonic (v3.8.13, Protein Metrics Inc.) with mass tolerance set as 20 ppm for both
precursors and fragments. The search output was filtered at 0.1% false discovery rate and 10
ppm mass error. The spectra assigned as cross-linked peptides were manually evaluated for
Cys0015 and Cys0136.

Analysis of Site-Specific N-linked Glycopeptides for SARS-Cov-2 S and Human ACE2 Proteins by LC-MS

640 Four 3.5-µg aliguots of SARS-CoV-2 S protein were reduced by incubating with 10 mM of 641 dithiothreitol at 56 °C and alkylated by 27.5 mM of iodoacetamide at room temperature in dark. 642 The four aliquots of proteins were then digested respectively using alpha lytic protease, 643 chymotrypsin, a combination of trypsin and Glu-C, or a combination of Glu-C and AspN. Three 644 10-µg aliguots of ACE2 protein were reduced by incubating with 5 mM of dithiothreitol at 56 °C 645 and alkylated by 13.75 mM of iodoacetamide at room temperature in dark. The three aliquots of 646 proteins were then digested respectively using alpha lytic protease, chymotrypsin, or a 647 combination of trypsin and Lys-C. The resulting peptides were separated on an Acclaim 648 PepMap RSLC C18 column (75 µm x 15 cm) and eluted into the nano-electrospray ion source 649 of an Orbitrap Fusion[™] Lumos[™] Tribrid[™] mass spectrometer at a flow rate of 200 nL/min. The 650 elution gradient consists of 1-40% acetonitrile in 0.1% formic acid over 370 minutes followed by 651 10 minutes of 80% acetonitrile in 0.1% formic acid. The spray voltage was set to 2.2 kV and the 652 temperature of the heated capillary was set to 280 °C. Full MS scans were acquired from m/z 653 200 to 2000 at 60k resolution, and MS/MS scans following higher-energy collisional dissociation 654 (HCD) with stepped collision energy (15%, 25%, 35%) were collected in the Orbitrap at 15k 655 resolution. pGlyco v2.2.2 (43) was used for database searches with mass tolerance set as 20 656 ppm for both precursors and fragments. The database search output was filtered to reach a 1%

- false discovery rate for glycans and 10% for peptides. Quantitation was performed by
- 658 calculating spectral counts for each glycan composition at each site. Any N-linked glycan
- 659 compositions identified by only one spectra were removed from quantitation. N-linked glycan
- 660 compositions were categorized into 22 classes (including Unoccupied):
- 661 HexNAc(2)Hex(9~5)Fuc(0~1) was classified as M9 to M5 respectively;
- 662 HexNAc(2)Hex(4~1)Fuc(0~1) was classified as M1-M4;
- 663 HexNAc(3~6)Hex(5~9)Fuc(0)NeuAc(0~1) was classified as Hybrid with
- 664 HexNAc(3~6)Hex(5~9)Fuc(1~2)NeuAc(0~1) classified as F-Hybrid; Complex-type glycans are
- 665 classified based on the number of antenna, fucosylation, and sulfation:
- 666 HexNAc(3)Hex(3~4)Fuc(0)NeuAc(0~1) is assigned as A1 with
- 667 HexNAc(3)Hex(3~4)Fuc(1~2)NeuAc(0~1) assigned as F-A1;
- 668 HexNAc(4)Hex(3~5)Fuc(0)NeuAc(0~2) is assigned as A2/A1B with
- 669 HexNAc(4)Hex(3~5)Fuc(1~5)NeuAc(0~2) assigned as F-A2/A1B;
- 670 HexNAc(5)Hex(3~6)Fuc(0)NeuAc(0~3) is assigned as A3/A2B with
- 671 HexNAc(5)Hex(3~6)Fuc(1~3)NeuAc(0~3) assigned as F-A3/A2B;
- 672 HexNAc(6)Hex(3~7)Fuc(0)NeuAc(0~4) is assigned as A4/A3B with
- 673 HexNAc(6)Hex(3~7)Fuc(1~3)NeuAc(0~4) assigned as F-A4/A3B;
- 674 HexNAc(7)Hex(3~8)Fuc(0)NeuAc(0~1) is assigned as A5/A4B with
- 675 HexNAc(7)Hex(3~8)Fuc(1~3)NeuAc(0~1) as F-A5/A4B; HexNAc(8)Hex(3~9)Fuc(0) is assigned
- as A6/A5B with HexNAc(8)Hex(3~9)Fuc(1) assigned as F-A6/A5B; any glycans identified with a
- 677 sulfate are assigned as Sulfated.

678 Analysis of Deglycosylated SARS-Cov-2 S and Human ACE2 Proteins by LC-MS

- Three 3.5-µg aliquots of SARS-CoV-2 S protein were reduced by incubating with 10 mM of
- 680 dithiothreitol at 56 °C and alkylated by 27.5 mM of iodoacetamide at room temperature in dark.
- The three aliquots were then digested respectively using chymotrypsin, Asp-N, or a combination
- of trypsin and Glu-C. Two 10-µg aliquots of ACE2 protein were reduced by incubating with 5

683 mM of dithiothreitol at 56 °C and alkylated by 13.75 mM of iodoacetamide at room temperature 684 in dark. The two aliquots were then digested respectively using chymotrypsin, or a combination 685 of trypsin and Lys-C. Following digestion, the proteins were deglycosylated by Endoglycosidase 686 H followed by PNGaseF treatment in the presence of ¹⁸O water. The resulting peptides were 687 separated on an Acclaim PepMap RSLC C18 column (75 µm x 15 cm) and eluted into the nano-688 electrospray ion source of an Orbitrap Fusion[™] Lumos[™] Tribrid[™] mass spectrometer at a flow 689 rate of 200 nL/min. The elution gradient consists of 1-40% acetonitrile in 0.1% formic acid over 690 370 minutes followed by 10 minutes of 80% acetonitrile in 0.1% formic acid. The spray voltage 691 was set to 2.2 kV and the temperature of the heated capillary was set to 280 °C. Full MS scans 692 were acquired from m/z 200 to 2000 at 60k resolution, and MS/MS scans following collision-693 induced dissociation (CID) at 38% collision energy were collected in the ion trap. The spectra 694 were analyzed using SEQUEST (Proteome Discoverer 1.4) with mass tolerance set as 20 ppm 695 for precursors and 0.5 Da for fragments. The search output was filtered using ProteolQ (v2.7) to 696 reach a 1% false discovery rate at protein level and 10% at peptide level. Occupancy of each N-697 linked glycosylation site was calculated using spectral counts assigned to the ¹⁸O-Asp-698 containing (PNGaseF-cleaved) and/or HexNAc-modified (EndoH-cleaved) peptides and their 699 unmodified counterparts.

Analysis of Site-Specific O-linked Glycopeptides for SARS-Cov-2 S and Human ACE2 Proteins by LC-MS

Three 10-µg aliquots of SARS-CoV-2 S protein and one 10-µg aliquot of ACE2 protein were reduced by incubating with 5 mM of dithiothreitol at 56 °C and alkylated by 13.75 mM of iodoacetamide at room temperature in dark. The four aliquots were then digested respectively using trypsin, Lys-C, Arg-C, or a combination of trypsin and Lys-C. Following digestion, the proteins were deglycosylated by PNGaseF treatment and then digested with O-protease OpeRATOR®. The resulting peptides were separated on an Acclaim PepMap RSLC C18 column (75 µm x 15 cm) and eluted into the nano-electrospray ion source of an Orbitrap

Fusion[™] Lumos[™] Tribrid[™] mass spectrometer at a flow rate of 200 nL/min. The elution 709 gradient consists of 1-40% acetonitrile in 0.1% formic acid over 370 minutes followed by 10 710 711 minutes of 80% acetonitrile in 0.1% formic acid. The spray voltage was set to 2.2 kV and the 712 temperature of the heated capillary was set to 280 °C. Full MS scans were acquired from m/z 713 200 to 2000 at 60k resolution, and MS/MS scans following higher-energy collisional dissociation 714 (HCD) with stepped collision energy (15%, 25%, 35%) or electron transfer dissociation (ETD) 715 were collected in the Orbitrap at 15k resolution. The raw spectra were analyzed by Byonic 716 (v3.8.13) with mass tolerance set as 20 ppm for both precursors and fragments. MS/MS filtering 717 was applied to only allow for spectra where the oxonium ions of HexNAc were observed. The 718 search output was filtered at 0.1% false discovery rate and 10 ppm mass error. The spectra 719 assigned as O-linked glycopeptides were manually evaluated. Quantitation was performed by 720 calculating spectral counts for each glycan composition at each site. Any O-linked glycan 721 compositions identified by only one spectra were removed from quantitation. Occupancy of each 722 O-linked glycosylation site was calculated using spectral counts assigned to any glycosylated 723 peptides and their unmodified counterparts from searches without MS/MS filtering.

724 Sequence Analysis of SARS-CoV-2 S and Human ACE2 Proteins

725 The genomes of SARS-CoV as well as bat and pangolin coronavirus sequences reported to be 726 closely related to SARS-CoV-2 were downloaded from NCBI. The S protein sequences from all 727 of those genomes were aligned using EMBOSS needle v6.6.0 (61) via the EMBL-EBI provided 728 web service (69). Manual analysis was performed in the regions containing canonical N-729 alycosylation sequons (N-X-S/T). For further sequence analysis of SARS-CoV-2 S variants, the 730 genomes of SARS-CoV-2 were downloaded from NCBI and GISAID and further processed 731 using Biopython 1.76 to extract all sequences annotated as "surface glycoprotein" and to 732 remove any incomplete sequence as well as any sequence containing unassigned amino acids. 733 For sequence analysis of human ACE2 variants, the single nucleotide polymorphisms (SNPs) of 734 ACE2 were extracted from the NCBI dbSNP database and filtered for missense mutation entries 735 with a reported minor allele frequency. Manual analysis was performed on both SARS-CoV-2 S

and human ACE2 variants to further examine the regions containing canonical N-glycosylation

737 sequons (N-X-S/T). LibreOffice Writer was used to shade regions on the linear sequence of S

and ACE2.

739 **3D Structural Modeling and Molecular Dynamics Simulation of Glycosylated SARS-CoV-2**

740 S and Human ACE2 Proteins

SARS-CoV2 Spike (S) protein structure and ACE2 co-complex – A 3D structure of the prefusion

form of the S protein (RefSeq: YP_009724390.1, UniProt: P0DTC2 SPIKE_SARS2), based on a

743 Cryo-EM structure (PDB code 6VSB) (48), was obtained from the SWISS-MODEL server

(swissmodel.expasy.org). The model has 95% coverage (residues 27 to 1146) of the S protein.

745 The receptor binding domain (RBD) in the "open" conformation was replaced with the RBD from

an ACE2 co-complex (PDB code 6M0J) by grafting residues C336 to V524.

747 *Glycoform generation* – Glycans (detected by glycomics) were selected for installation on

748 glycosylated S and ACE2 sequons (detected by glycoproteomics) based on three sets of criteria

designed to reasonably capture different aspects of glycosylation microheterogeneity. We

750 denote the first of these glycoform models as "Abundance." The glycans selected for

installation to generate the Abundance model were chosen because they were identified as the

most abundant glycan structure (detected by glycomics) that matched the most abundant glycan

composition (detected by glycoproteomics) at each individual site. We denote the second

754 glycoform model as "Oxford Class." The glycans selected for installation to generate the Oxford

755 Class model were chosen because they were the most abundant glycan structure, (detected by

glycomics) that was contained within the most highly represented Oxford classification group

757 (detected by glycoproteomics) at each individual site (**Fig. S7**, **Supplemental Table**, **Tabs 1,8**).

Finally, we denote the third glycoform model as "Processed." The glycans selected for

installation to generate the Processed model were chosen because they were the most highly

760 trimmed, elaborated, or terminally decorated structure (detected by glycomics) that

761 corresponded to a composition (detected by glycoproteomics) which was present at $\geq 1/3^{rd}$ of 762 the abundance of the most highly represented composition at each site (Supplemental Table, 763 Tab 1). 3D structures of the three glycoforms (Abundance, Oxford Class, Processed) were 764 generated for the SARS-CoV2 S protein alone, and in complex with the glycosylated ACE2 765 protein. The glycoprotein builder available at GLYCAM-Web (www.glycam.org) was employed 766 together with an in-house program that adjusts the asparagine side chain torsion angles and 767 glycosidic linkages within known low-energy ranges (70) to relieve any atomic overlaps with the 768 core protein, as described previously (71,72).

769 Energy minimization and Molecular dynamics (MD) simulations - Each glycosylated structure 770 was placed in a periodic box of TIP3P water molecules with a 10 Å buffer between the solute 771 and the box edge. Energy minimization of all atoms was performed for 20,000 steps (10,000 772 steepest decent, followed by 10,000 conjugant gradient) under constant pressure (1 atm) and 773 temperature (300 K) conditions. All MD simulations were performed under nPT conditions with 774 the CUDA implementation of the PMEMD (73,74) simulation code, as present in the Amber14 775 software suite (University of California, San Diego). The GLYCAM06j force field (75) and 776 Amber14SB force field (76) were employed for the carbohydrate and protein moieties, 777 respectively. A Berendsen barostat with a time constant of 1 ps was employed for pressure regulation, while a Langevin thermostat with a collision frequency of 2 ps⁻¹ was employed for 778 779 temperature regulation. A nonbonded interaction cut-off of 8 Å was employed. Long-range 780 electrostatics were treated with the particle-mesh Ewald (PME) method (77). Covalent bonds 781 involving hydrogen were constrained with the SHAKE algorithm, allowing an integration time 782 step of 2 fs to be employed. The energy minimized coordinates were equilibrated at 300K over 783 400 ps with restraints on the solute heavy atoms. Each system was then equilibrated with 784 restraints on the C α atoms of the protein for 1ns, prior to initiating 4 independent 250 ns 785 production MD simulations with random starting seeds for a total time of 1 µs per system, with 786 no restraints applied.

Antigenic surface analysis. A series of 3D structure snapshots of the simulation were taken at 1
 ns intervals and analysed in terms of their ability to interact with a spherical probe based on the

average size of hypervariable loops present in an antibody complementarity determining region

790 (CDR), as described recently (<u>https://www.biorxiv.org/content/10.1101/2020.04.07.030445v2</u>).

The percentage of simulation time each residue was exposed to the AbASA probe was

calculated and plotted onto both the 3D structure and primary sequence.

793

794 Analysis of SARS-CoV-2 Spike VSV pseudoparticles (ppVSV-SARS-2-S)

795 293T cells were transfected with an expression plasmid encoding SARS-CoV-2 Spike

796 (pcDNAintron-SARS-2-S∆19). To increase cell surface expression, the last 19 amino acids

containing the Golgi retention signal were removed. Two SA19 constructs were compared, one

started with Met1 and the other with Met2. Twenty-four hours following transfection, cells were

transduced with ppVSV∆G-VSV-G (particles that were pseudotyped with VSV-G in trans). One

800 hour following transduction cells were extensively washed and media was replaced.

801 Supernatant containing particles were collected 12-24 hour following transduction and cleared

802 through centrifugation. Cleared supernatant was frozen at -80°C for future use. Target cells

803 VeroE6 were seeded in 24-well plates $(5x10^5 \text{ cells/mL})$ at a density of 80% coverage. The

following day, ppVSV-SARS-2-S/GFP particles were transduced into target cells for 60 minutes,

805 particles pseudotyped with VSV-G, Lassa virus GP, or no glycoprotein were included as

806 controls. 24 hours following transduction, transduced cells were released from the plate with

807 trypsin, fixed with 4% formaldehyde, and GFP-positive virus-transduced cells were quantified

808 using flow cytometry (Bectin Dickson BD-LSRII). To quantify the ability of various SARS-CoV-2

809 S mutants to mediate fusion, effector cells (HEK293T) were transiently transfected with the

810 indicated pcDNAintron-SARS-2-S expression vector or measles virus H and F (78). Effector

811 cells were infected with MVA-T7 four hours following transduction to produce the T7 polymerase

812 (79). Target cells naturally expressing the receptor ACE2 (Vero) or ACE2 negative cells

- 813 (HEK293T) were transfected with pTM1-luciferase, which encodes for firefly luciferase under the
- control of a T7 promoter (80). 24 hours following transfection, the target cells were lifted and
- added to the effector cells at a 1:1 ratio. 4 hours following co-cultivation, cells were washed,
- 816 lysed and luciferase levels were quantified using Promega's Steady-Glo substrate. To visualize
- 817 cell-to-cell fusion, Vero cells were co-transfected with pGFP and the pcDNAintron-SARS-2-S
- 818 constructs. 24 hours following transfection, syncytia was visualized by fluorescence microscopy.

819 **DATA AVAILABILITY**

- 820 The mass spectrometry proteomics data are available via ProteomeXchange with identifiers
- 821 listed in the KEY RESOURCES TABLE.

822 SUPPLEMENTAL INFORMATION

- Tables (1, 16 tabs), Figures (7), Movies (4), and Simulations (3).
- 824 **SUPPLEMENTAL LEGEND**:
- 825 **Supplemental Table Tab 1**. Glycans modeled as Abundance, Oxford Class, and Processed.
- 826 **Supplemental Table Tab 2.** Cys0015-Cys0136 Disulfide Linked Peptide for SARS-CoV-2 S.
- 827 Supplemental Table Tab 3. Detection of N-linked glycans released from SARS-CoV-2 S and
- human ACE2. Relative abundance (prevalence) of each species is calculated based on peak
- intensity in full MS.
- 830 **Supplemental Table Tab 4**. Detection of O-linked glycans released from SARS-CoV-2 S and
- human ACE2. Relative abundance (prevalence) of each species is calculated based on peak
- intensity in full MS.
- 833 **Supplemental Table Tab 5**. N-linked glycan occupancy at each site of SARS-CoV-2 S and
- human ACE2. Occupancy is calculated using spectral counts assigned to the 18O-Asp-
- 835 containing (PNGaseF-cleaved) and/or HexNAc-modified (EndoH-cleaved) peptides and their
- unmodified counterparts. Sequon refers to the Asn-x-Ser/Thr/Cys, Asn-Gly-x sequences.
- 837 Supplemental Table Tab 6. N-linked glycan compositions identified at each site of SARS-CoV-
- 2 S and human ACE2. Asn(N)# indicates the numbers of asparagines in protein sequences. In

839 compositions; N=HexNAc, H=Hexose (Hex), F=Fucose (Fuc), A=Neu5Ac, S=Sulfate, In fucosylation: NoFuc=No Fuc identified; 1Core=One Fuc identified at core position; 1Term=One 840 841 Fuc identified at terminal position: 1Core and 1Term=One Fuc identified as a mixture of core 842 and terminal positions; 1Core1Term=Two Fuc identified and one is at core and the other is at 843 terminal: 2Term=Two Fuc identified at terminal positions: 1Core1Term and 2Term=Two Fuc 844 identified as a mixture of core and terminal positions; 1Core2Term=Three Fuc identified and 845 one is at core and the others are at terminal; 3Term=Three Fuc identified at terminal positions; 846 1Core2Term and 3Term=Three Fuc identified as a mixture of core and terminal positions: 847 1Core3Term=Four Fuc identified and one is at core and the others are at terminal; 4Term=Four 848 Fuc identified at terminal positions; 1Core3Term and 4Term=Four Fuc identified as a mixture of 849 core and terminal positions; 1Core4Term=Five Fuc identified and one is at core and the others 850 are at terminal. 851 Supplemental Table Tab 7. N-linked glycan types identified at each site of SARS-CoV-2 S and 852 human ACE2. All N-linked glycans are categorized into 3 types: high-mannose, hybrid and 853 complex. 854 Supplemental Table Tab 8. N-linked glycan oxford classes identified at each site of SARS-855 CoV-2 S and human ACE2. All N-linked glycan compositions are categorized into 22 classes: 856 M9 to M5 respectively is defined as HexNAc(2)Hex(9~5)Fuc(0~1); M1-M4 is defined as 857 HexNAc(2)Hex(4~1)Fuc(0~1); Hybrid is defined as HexNAc(3~6)Hex(5~9)Fuc(0)NeuAc(0~1) 858 and F-Hybrid is defined as HexNAc(3~6)Hex(5~9)Fuc(1~2)NeuAc(0~1). Complex-type glycans 859 are classified based on the number of antenna, fucosylation, and sulfation: 860 HexNAc(3)Hex(3~4)Fuc(0)NeuAc(0~1) is assigned as A1 with 861 HexNAc(3)Hex(3~4)Fuc(1~2)NeuAc(0~1) assigned as F-A1; 862 HexNAc(4)Hex(3~5)Fuc(0)NeuAc(0~2) is assigned as A2/A1B with 863 HexNAc(4)Hex(3~5)Fuc(1~5)NeuAc(0~2) assigned as F-A2/A1B; 864 HexNAc(5)Hex(3~6)Fuc(0)NeuAc(0~3) is assigned as A3/A2B with

- HexNAc(5)Hex($3\sim6$)Fuc($1\sim3$)NeuAc($0\sim3$) assigned as F-A3/A2B;
- 866 HexNAc(6)Hex(3~7)Fuc(0)NeuAc(0~4) is assigned as A4/A3B with
- 867 HexNAc(6)Hex(3~7)Fuc(1~3)NeuAc(0~4) assigned as F-A4/A3B;
- 868 HexNAc(7)Hex(3~8)Fuc(0)NeuAc(0~1) is assigned as A5/A4B with
- HexNAc(7)Hex(3~8)Fuc(1~3)NeuAc(0~1) assigned as F-A5/A4B; HexNAc(8)Hex(3~9)Fuc(0) is
- 870 assigned as A6/A5B with HexNAc(8)Hex(3~9)Fuc(1) assigned as F-A6/A5B; any glycans
- identified with a sulfate are assigned as Sulfated.
- 872 Supplemental Table Tab 9. O-linked glycan compositions identified at each site of SARS-CoV-
- 873 2 S and human ACE2. Ser/Thr# indicates the numbers of serines or threonines in protein
- 874 sequences. In compositions: N=HexNAc, H=Hexose (Hex), F=Fucose (Fuc), and A=Neu5Ac.
- 875 **Supplemental Table Tab 10**. O-linked glycan occupancy at each site of SARS-CoV-2 S and
- 876 human ACE2. Occupancy is calculated using spectral counts assigned to the glycosylated
- 877 peptides and their unmodified counterparts.
- 878 **Supplemental Table Tab 11**. SARS-CoV-2 S and human ACE2 variants.
- 879 **Supplemental Table Tab 12**. Proteomic Analyses of purified S and ACE2.
- 880 **Supplemental Table Tab 13.** Sulfated N-linked glycans released from SARS-CoV-2 S.
- Following permethylation, almost all of the sulfated hybrid and complex N-glycans are recovered
- in the organic phase despite their anionic charge. Organic phase permethylated glycans were
- analyzed by mass spectrometry using negative ion mode. The indicated glycan structures are
- consistent with the compositions detected at the m/z values shown.
- 885 **Supplemental Table Tab 14.** Surface Antigen Exposure of Abundance Glycosylated S. The
- scale used is 0 (not accessible) to 1.0 (fully accessible).
- 887 **Supplemental Table Tab 15.** ACE2-Glycan-S-Peptide Interactions.
- The scale used is 0 (no interaction) to 1.0 (interacted throughout entire simulation).
- 889 **Supplemental Table Tab 16.** S-Glycan-ACE2-Peptide Interactions.
- 890 The scale used is 0 (no interaction) to 1.0 (interacted throughout entire simulation).

891

- 892 **Supplemental Figure S1**. Defining N-terminus of ACE2 as pyro-glutamine at site Q0018.
- 893 Representative HCD MS2 spectrum shown.
- 894 Supplemental Figure S2. Disulfide bond formed between Cysteines 0015 and 0136 of SARS-
- 895 CoV-2 S. Representative EThcD MS2 spectrum shown.
- 896 Supplemental Figure S3. Signal P prediction of two different start methionines for SARS-CoV-

897 2 S.

- 898 **Supplemental Figure S4**. Functional characterization of various S constructs in Pseudovirus.
- (A) Syncytia produced by SARS-CoV-2 S constructs in VeroE6 cells co-transfected with a GFP
- 900 plasmid to visualize cell-to-cell fusion. Quantification of fusion using a luciferase
- 901 complementation assay in 293T (B) or VeroE6 cells (C). (D) Transduction efficiency in Vero E6
- 902 cells of ppVSV-GFP particles coated in the indicated glycoprotein. Results suggest that start
- 903 methionine does not alter fusion or efficiency.
- 904 **Supplemental Figure S5**. Detection of O-linked glycans released from SARS-CoV-2 S and
- 905 human ACE2. The detected O-glycans were categorized based on their structures and types.
- 906 Relative abundance (prevalence) of each species is calculated based on peak intensity in full

907 MS.

- 908 **Supplemental Figure S6**. O-linked glycans detected at site T0323 of SARS-CoV-2 S.
- 909 Representative Step-HCD spectra shown for 6 glycoforms.
- 910 **Supplemental Figure S7**. Sequence alignments of SARS-CoV-1 and SARS-CoV-2 S variants
- 911 as well as alignment of multiple S proteins from related coronaviruses.
- 912 Supplemental Movie A: Linked to Figure 4C, Glycosylated S antigen accessibility
- 913 **Supplemental Movie B:** Linked to Figure 6A, Glycosylated ACE2 with variants
- 914 **Supplemental Movie C:** Linked to Figure 7C, Interface of ACE2-S Complex
- 915 **Supplemental Movie D:** Linked to Figure 7C, the glycosylated ACE2-S Complex
- 916 **Simulation 1:** Linked to Figure 7A, Abundance glycoforms on ACE2-S Complex

917	Simulation 2:	Linked to	Figure 7A.	Oxford class	alvcoforms on	ACE2-S Complex
	• • • = .			• / . • . • . • . • . • . •	9.900.0	

Simulation 3: Linked to Figure 7A, Processed glycoforms on ACE2-S Complex

REFERENCES

921	1.	Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B.,
922		Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen,
923		X. R., Wang, X., Zheng, X. S., Zhao, K., Chen, Q. J., Deng, F., Liu, L. L., Yan, B., Zhan, F. X.,
924		Wang, Y. Y., Xiao, G. F., and Shi, Z. L. (2020) A pneumonia outbreak associated with a
925		new coronavirus of probable bat origin. <i>Nature</i> 579 , 270-273
926	2.	Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi,
927		Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng,
928		Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W. J., Wang, D., Xu, W., Holmes, E. C.,
929		Gao, G. F., Wu, G., Chen, W., Shi, W., and Tan, W. (2020) Genomic characterisation
930		and epidemiology of 2019 novel coronavirus: implications for virus origins and
931		receptor binding. Lancet 395 , 565-574
932	3.	Zhong, N. S., Zheng, B. J., Li, Y. M., Poon, Xie, Z. H., Chan, K. H., Li, P. H., Tan, S. Y.,
933		Chang, Q., Xie, J. P., Liu, X. Q., Xu, J., Li, D. X., Yuen, K. Y., Peiris, and Guan, Y. (2003)
934		Epidemiology and cause of severe acute respiratory syndrome (SARS) in
935		Guangdong, People's Republic of China, in February, 2003. Lancet 362 , 1353-1358
936	4.	Xia, X. (2020) Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host
937		antiviral defense. <i>Mol Biol Evol</i>
938	5.	Zhang, T., Wu, Q., and Zhang, Z. (2020) Probable Pangolin Origin of SARS-CoV-2
939		Associated with the COVID-19 Outbreak. Curr Biol 30 , 1346-1351 e1342
940	6.	Alijotas-Reig, J., Esteve-Valverde, E., Belizna, C., Selva-O'Callaghan, A., Pardos-Gea, J.,
941		Quintana, A., Mekinian, A., Anunciacion-Llunell, A., and Miro-Mur, F. (2020)
942		Immunomodulatory therapy for the management of severe COVID-19. Beyond the
943		anti-viral therapy: A comprehensive review. Autoimmun Rev 19, 102569
944	7.	Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C.,
945		Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R.
946		W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A.,
947		Short, W. R., Touloumi, G., Lye, D. C., Ohmagari, N., Oh, M. D., Ruiz-Palacios, G. M.,
948		Benfield, T., Fatkenheuer, G., Kortepeter, M. G., Atmar, R. L., Creech, C. B., Lundgren,
949		J., Babiker, A. G., Pett, S., Neaton, J. D., Burgess, T. H., Bonnett, T., Green, M.,
950		Makowski, M., Osinusi, A., Nayak, S., Lane, H. C., and Members, AS. G. (2020)
951		Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med
952	8.	Beun, R., Kusadasi, N., Sikma, M., Westerink, J., and Huisman, A. (2020)
953		Thromboembolic events and apparent heparin resistance in patients infected with
954		SARS-CoV-2. Int J Lab Hematol 42 Suppl 1, 19-20
955	9.	Dashti-Khavidaki, S., and Khalili, H. (2020) Considerations for Statin Therapy in
956		Patients with COVID-19. Pharmacotherapy 40, 484-486
957	10.	Fedson, D. S., Opal, S. M., and Rordam, O. M. (2020) Hiding in Plain Sight: an
958		Approach to Treating Patients with Severe COVID-19 Infection. <i>mBio</i> 11
		-

Shi, Q., Zhou, Q., Wang, X., Liao, J., Yu, Y., Wang, Z., Lu, S., Ma, Y., Xun, Y., Luo, X., Li, W.,

959

11.

960 Fukuoka, T., Ahn, H. S., Lee, M. S., Luo, Z., Liu, E., Chen, Y., Li, Q., Yang, K., Guan, Q., 961 Evidence, C.-., and Recommendations Working, G. (2020) Potential effectiveness and 962 safety of antiviral agents in children with coronavirus disease 2019: a rapid review 963 and meta-analysis. Ann Transl Med 8, 624 964 12. Tang, N., Bai, H., Chen, X., Gong, J., Li, D., and Sun, Z. (2020) Anticoagulant treatment 965 is associated with decreased mortality in severe coronavirus disease 2019 patients 966 with coagulopathy. *J Thromb Haemost* 18, 1094-1099 967 13. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., 968 Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C., and 969 Pohlmann, S. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 970 Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280 e278 971 14. Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., 972 Sullivan, J. L., Luzuriaga, K., Greenough, T. C., Choe, H., and Farzan, M. (2003) 973 Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. 974 *Nature* **426**, 450-454 975 15. Watanabe, Y., Bowden, T. A., Wilson, I. A., and Crispin, M. (2019) Exploitation of 976 glycosylation in enveloped virus pathobiology. *Biochim Biophys Acta Gen Subj* **1863**, 977 1480-1497 978 16. Li, F. (2016) Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu 979 *Rev Virol* **3**, 237-261 980 Lei, C., Qian, K., Li, T., Zhang, S., Fu, W., Ding, M., and Hu, S. (2020) Neutralization of 17. 981 SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. *Nat Commun* **11**, 982 2070 983 Monteil, V., Kwon, H., Prado, P., Hagelkruys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., 18. 984 Garreta, E., Hurtado Del Pozo, C., Prosper, F., Romero, J. P., Wirnsberger, G., Zhang, 985 H., Slutsky, A. S., Conder, R., Montserrat, N., Mirazimi, A., and Penninger, J. M. (2020) 986 Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-987 Grade Soluble Human ACE2. Cell 181, 905-913 e907 988 19. Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., and Crispin, M. (2020) Site-989 specific glycan analysis of the SARS-CoV-2 spike. *Science* 990 Watanabe, Y., Berndsen, Z. T., Raghwani, J., Seabright, G. E., Allen, J. D., Pybus, O. G., 20. 991 McLellan, J. S., Wilson, I. A., Bowden, T. A., Ward, A. B., and Crispin, M. (2020) 992 Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat 993 *Commun* **11**. 2688 994 21. Stertz, S., Reichelt, M., Spiegel, M., Kuri, T., Martinez-Sobrido, L., Garcia-Sastre, A., 995 Weber, F., and Kochs, G. (2007) The intracellular sites of early replication and 996 budding of SARS-coronavirus. Virology 361, 304-315 997 Ujike, M., and Taguchi, F. (2015) Incorporation of spike and membrane 22. 998 glycoproteins into coronavirus virions. *Viruses* **7**, 1700-1725 999 Shajahan, A., Supekar, N. T., Gleinich, A. S., and Azadi, P. (2020) Deducing the N- and 23. 1000 O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. 1001 Glycobiology 1002 Ritchie, G., Harvey, D. J., Feldmann, F., Stroeher, U., Feldmann, H., Royle, L., Dwek, R. 24. 1003 A., and Rudd, P. M. (2010) Identification of N-linked carbohydrates from severe 1004 acute respiratory syndrome (SARS) spike glycoprotein. Virology 399, 257-269

1005	25.	Duan, H., Chen, X., Boyington, J. C., Cheng, C., Zhang, Y., Jafari, A. J., Stephens, T.,
1006		Tsybovsky, Y., Kalyuzhniy, O., Zhao, P., Menis, S., Nason, M. C., Normandin, E.,
1007		Mukhamedova, M., DeKosky, B. J., Wells, L., Schief, W. R., Tian, M., Alt, F. W., Kwong,
1008		P. D., and Mascola, J. R. (2018) Glycan Masking Focuses Immune Responses to the
1009		HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor
1010		Antibodies. <i>Immunity</i> 49 , 301-311 e305
1011	26.	Escolano, A., Gristick, H. B., Abernathy, M. E., Merkenschlager, J., Gautam, R., Oliveira,
1012		T. Y., Pai, J., West, A. P., Jr., Barnes, C. O., Cohen, A. A., Wang, H., Golijanin, J., Yost, D.,
1013		Keeffe, J. R., Wang, Z., Zhao, P., Yao, K. H., Bauer, J., Nogueira, L., Gao, H., Voll, A. V.,
1014		Montefiori, D. C., Seaman, M. S., Gazumyan, A., Silva, M., McGuire, A. T., Stamatatos, L.,
1015		Irvine, D. J., Wells, L., Martin, M. A., Bjorkman, P. J., and Nussenzweig, M. C. (2019)
1016		Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.
1017		Nature 570 , 468-473
1018	27.	Seabright, G. E., Cottrell, C. A., van Gils, M. J., D'Addabbo, A., Harvey, D. J., Behrens, A.
1019	_/.	J., Allen, J. D., Watanabe, Y., Scaringi, N., Polveroni, T. M., Maker, A., Vasiljevic, S., de
1020		Val, N., Sanders, R. W., Ward, A. B., and Crispin, M. (2020) Networks of HIV-1
1020		Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and
1021		Deletions. <i>Structure</i>
1022	28.	Yu, W. H., Zhao, P., Draghi, M., Arevalo, C., Karsten, C. B., Suscovich, T. J., Gunn, B.,
1023	20.	Streeck, H., Brass, A. L., Tiemeyer, M., Seaman, M., Mascola, J. R., Wells, L.,
1021		Lauffenburger, D. A., and Alter, G. (2018) Exploiting glycan topography for
1025		computational design of Env glycoprotein antigenicity. <i>PLoS Comput Biol</i> 14 ,
1020		e1006093
1027	29.	Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S.,
1020	<i>L J</i> .	Culap, K., Zatta, F., De Marco, A., Peter, A., Guarino, B., Spreafico, R., Cameroni, E.,
1029		Case, J. B., Chen, R. E., Havenar-Daughton, C., Snell, G., Telenti, A., Virgin, H. W.,
1030		Lanzavecchia, A., Diamond, M. S., Fink, K., Veesler, D., and Corti, D. (2020) Cross-
1031		neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i>
1032		583 , 290-295
1035	30.	Tikellis, C., Bernardi, S., and Burns, W. C. (2011) Angiotensin-converting enzyme 2 is
1034	50.	a key modulator of the renin-angiotensin system in cardiovascular and renal
1035		disease. <i>Curr Opin Nephrol Hypertens</i> 20 , 62-68
1030	31.	Lambert, D. W., Yarski, M., Warner, F. J., Thornhill, P., Parkin, E. T., Smith, A. I.,
1037	51.	Hooper, N. M., and Turner, A. J. (2005) Tumor necrosis factor-alpha convertase
1030		(ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory
1035		syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2
1040		(ACE2). <i>J Biol Chem</i> 280 , 30113-30119
1041	32.	Epelman, S., Shrestha, K., Troughton, R. W., Francis, G. S., Sen, S., Klein, A. L., and
1042	52.	Tang, W. H. (2009) Soluble angiotensin-converting enzyme 2 in human heart failure:
1043		relation with myocardial function and clinical outcomes. <i>J Card Fail</i> 15 , 565-571
1044	33.	Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., Wong, S. K., Huang, I. C., Xu, K.,
1045	55.	Vasilieva, N., Murakami, A., He, Y., Marasco, W. A., Guan, Y., Choe, H., and Farzan, M.
1040		(2005) Receptor and viral determinants of SARS-coronavirus adaptation to human
1047		ACE2. EMBO J 24, 1634-1643
1048	34.	Marth, J. D., and Grewal, P. K. (2008) Mammalian glycosylation in immunity. <i>Nat Rev</i>
1049	54.	Immunol 8 , 874-887
1020		

1051 1052 1053 1054 1055	35. 36.	Varki, A. (2017) Biological roles of glycans. <i>Glycobiology</i> 27 , 3-49 Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., Martinez, D. R., Loos, C., Atyeo, C., Fischinger, S., Burke, J. S., Slein, M. D., Chen, Y., Zuiani, A., FJ, N. L., Travers, M., Habibi,
1055		S., Pessaint, L., Van Ry, A., Blade, K., Brown, R., Cook, A., Finneyfrock, B., Dodson, A., Teow, E., Velasco, J., Zahn, R., Wegmann, F., Bondzie, E. A., Dagotto, G., Gebre, M. S.,
1050		He, X., Jacob-Dolan, C., Kirilova, M., Kordana, N., Lin, Z., Maxfield, L. F., Nampanya, F.,
1058		Nityanandam, R., Ventura, J. D., Wan, H., Cai, Y., Chen, B., Schmidt, A. G., Wesemann,
1059		D. R., Baric, R. S., Alter, G., Andersen, H., Lewis, M. G., and Barouch, D. H. (2020) DNA
1060		vaccine protection against SARS-CoV-2 in rhesus macaques. Science
1061	37.	Almagro Armenteros, J. J., Tsirigos, K. D., Sonderby, C. K., Petersen, T. N., Winther, O.,
1062		Brunak, S., von Heijne, G., and Nielsen, H. (2019) SignalP 5.0 improves signal peptide
1063	20	predictions using deep neural networks. <i>Nat Biotechnol</i> 37 , 420-423
1064	38.	Aoki, K., Perlman, M., Lim, J. M., Cantu, R., Wells, L., and Tiemeyer, M. (2007)
$\begin{array}{c} 1065\\ 1066 \end{array}$		Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila
1060	39.	melanogaster embryo. <i>J Biol Chem</i> 282 , 9127-9142 Aoki, K., Porterfield, M., Lee, S. S., Dong, B., Nguyen, K., McGlamry, K. H., and
1067	59.	Tiemeyer, M. (2008) The diversity of O-linked glycans expressed during Drosophila
1069		melanogaster development reflects stage- and tissue-specific requirements for cell
1070		signaling. J Biol Chem 283 , 30385-30400
1071	40.	Weatherly, D. B., Arpinar, F. S., Porterfield, M., Tiemeyer, M., York, W. S., and
1072		Ranzinger, R. (2019) GRITS Toolbox-a freely available software for processing,
1073		annotating and archiving glycomics mass spectrometry data. <i>Glycobiology</i> 29 , 452-
1074		460
1075	41.	Wang, S., Voronin, Y., Zhao, P., Ishihara, M., Mehta, N., Porterfield, M., Chen, Y.,
1076		Bartley, C., Hu, G., Han, D., Wells, L., Tiemeyer, M., and Lu, S. (2020) Glycan Profiles of
1077		gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different
1078	42.	Host Cell Lines under Non-GMP or GMP Conditions. <i>J Virol</i> 94
1079 1080	42.	Ruiz-Canada, C., Kelleher, D. J., and Gilmore, R. (2009) Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST
1080		isoforms. Cell 136 , 272-283
1081	43.	Zielinska, D. F., Gnad, F., Wisniewski, J. R., and Mann, M. (2010) Precision mapping of
1082	15.	an in vivo N-glycoproteome reveals rigid topological and sequence constraints. <i>Cell</i>
1084		141 , 897-907
1085	44.	Palmisano, G., Melo-Braga, M. N., Engholm-Keller, K., Parker, B. L., and Larsen, M. R.
1086		(2012) Chemical deamidation: a common pitfall in large-scale N-linked
1087		glycoproteomic mass spectrometry-based analyses. J Proteome Res 11, 1949-1957
1088	45.	Zhou, T., Doria-Rose, N. A., Cheng, C., Stewart-Jones, G. B. E., Chuang, G. Y., Chambers,
1089		M., Druz, A., Geng, H., McKee, K., Kwon, Y. D., O'Dell, S., Sastry, M., Schmidt, S. D., Xu,
1090		K., Chen, L., Chen, R. E., Louder, M. K., Pancera, M., Wanninger, T. G., Zhang, B., Zheng,
1091		A., Farney, S. K., Foulds, K. E., Georgiev, I. S., Joyce, M. G., Lemmin, T., Narpala, S.,
1092		Rawi, R., Soto, C., Todd, J. P., Shen, C. H., Tsybovsky, Y., Yang, Y., Zhao, P., Haynes, B. F.,
1093		Stamatatos, L., Tiemeyer, M., Wells, L., Scorpio, D. G., Shapiro, L., McDermott, A. B.,
1094 1095		Mascola, J. R., and Kwong, P. D. (2017) Quantification of the Impact of the HIV-1- Glycan Shield on Antibody Elicitation. <i>Cell Rep</i> 19 , 719-732
1095		diyean Smeld on Antibody Elicitation. Cen Kep 17, / 17-/ 32

1001		
1096	46.	Liu, M. Q., Zeng, W. F., Fang, P., Cao, W. Q., Liu, C., Yan, G. Q., Zhang, Y., Peng, C., Wu, J.
1097		Q., Zhang, X. J., Tu, H. J., Chi, H., Sun, R. X., Cao, Y., Dong, M. Q., Jiang, B. Y., Huang, J. M.,
1098		Shen, H. L., Wong, C. C. L., He, S. M., and Yang, P. Y. (2017) pGlyco 2.0 enables
1099		precision N-glycoproteomics with comprehensive quality control and one-step mass
1100	. –	spectrometry for intact glycopeptide identification. <i>Nat Commun</i> 8 , 438
1101	47.	Bern, M., Kil, Y. J., and Becker, C. (2012) Byonic: advanced peptide and protein
1102		identification software. Curr Protoc Bioinformatics Chapter 13, Unit13 20
1103	48.	Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., Graham, B.
1104		S., and McLellan, J. S. (2020) Cryo-EM structure of the 2019-nCoV spike in the
1105		prefusion conformation. <i>Science</i> 367 , 1260-1263
1106	49.	Ferreira, R. C., Grant, O. C., Moyo, T., Dorfman, J. R., Woods, R. J., Travers, S. A., and
1107		Wood, N. T. (2018) Structural Rearrangements Maintain the Glycan Shield of an HIV-
1108		1 Envelope Trimer After the Loss of a Glycan. <i>Sci Rep</i> 8 , 15031
1109	50.	Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., and
1110		Wang, X. (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound
1111		to the ACE2 receptor. <i>Nature</i> 581 , 215-220
1112	51.	Wang, C. C., Chen, J. R., Tseng, Y. C., Hsu, C. H., Hung, Y. F., Chen, S. W., Chen, C. M.,
1113		Khoo, K. H., Cheng, T. J., Cheng, Y. S., Jan, J. T., Wu, C. Y., Ma, C., and Wong, C. H. (2009)
1114		Glycans on influenza hemagglutinin affect receptor binding and immune response.
1115	-	Proc Natl Acad Sci U S A 106 , 18137-18142
1116	52.	Behrens, A. J., Harvey, D. J., Milne, E., Cupo, A., Kumar, A., Zitzmann, N., Struwe, W. B.,
1117		Moore, J. P., and Crispin, M. (2017) Molecular Architecture of the Cleavage-
1118		Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. <i>J Virol</i>
1119	F 2	91 Kristia I. Vuoleenia E. Monrie C. Klania I. Kasan T. Daashali I. Duois Delevais M
1120	53.	Kristic, J., Vuckovic, F., Menni, C., Klaric, L., Keser, T., Beceheli, I., Pucic-Bakovic, M.,
1121		Novokmet, M., Mangino, M., Thaqi, K., Rudan, P., Novokmet, N., Sarac, J., Missoni, S.,
1122 1123		Kolcic, I., Polasek, O., Rudan, I., Campbell, H., Hayward, C., Aulchenko, Y., Valdes, A., Wilson, J. F., Cornik, O., Brimoras, D., Zoldos, V., Spostor, T., and Laus, C. (2014)
1123		Wilson, J. F., Gornik, O., Primorac, D., Zoldos, V., Spector, T., and Lauc, G. (2014) Glycans are a novel biomarker of chronological and biological ages. <i>J Gerontol A Biol</i>
1124		Sci Med Sci 69, 779-789
1125	54.	Pavic, T., Dilber, D., Kifer, D., Selak, N., Keser, T., Ljubicic, D., Vukic Dugac, A., Lauc, G.,
1120	54.	Rumora, L., and Gornik, O. (2018) N-glycosylation patterns of plasma proteins and
1127		immunoglobulin G in chronic obstructive pulmonary disease. J Transl Med 16 , 323
1120	55.	Rudman, N., Gornik, O., and Lauc, G. (2019) Altered N-glycosylation profiles as
1130	55.	potential biomarkers and drug targets in diabetes. <i>FEBS Lett</i> 593 , 1598-1615
1130	56.	Gebrehiwot, A. G., Melka, D. S., Kassaye, Y. M., Rehan, I. F., Rangappa, S., Hinou, H.,
1131	00.	Kamiyama, T., and Nishimura, S. I. (2018) Healthy human serum N-glycan profiling
1132		reveals the influence of ethnic variation on the identified cancer-relevant glycan
1134		biomarkers. <i>PLoS One</i> 13 , e0209515
1135	57.	Wrobel, A. G., Benton, D. J., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J.
1136	2	J., and Gamblin, S. J. (2020) SARS-CoV-2 and bat RaTG13 spike glycoprotein
1137		structures inform on virus evolution and furin-cleavage effects. <i>Nat Struct Mol Biol</i>
1138	58.	Casalino, L., Gaieb, Z., Dommer, A. C., Harbison, A. M., Fogarty, C. A., Barros, E. P.,
1139	-	Taylor, B. C., Fadda, E., and Amaro, R. E. (2020) Shielding and Beyond: The Roles of
1140		Glycans in SARS-CoV-2 Spike Protein. <i>bioRxiv</i>

4 4 4 4	50	
1141	59.	Struwe, W. B., Chertova, E., Allen, J. D., Seabright, G. E., Watanabe, Y., Harvey, D. J.,
1142		Medina-Ramirez, M., Roser, J. D., Smith, R., Westcott, D., Keele, B. F., Bess, J. W., Jr.,
1143		Sanders, R. W., Lifson, J. D., Moore, J. P., and Crispin, M. (2018) Site-Specific
1144		Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric
1145		Immunogen. <i>Cell Rep</i> 24 , 1958-1966 e1955
1146	60.	Thieker, D. F., Hadden, J. A., Schulten, K., and Woods, R. J. (2016) 3D implementation
1147		of the symbol nomenclature for graphical representation of glycans. <i>Glycobiology</i>
1148		26 , 786-787
1149	61.	Rice, P., Longden, I., and Bleasby, A. (2000) EMBOSS: the European Molecular
1150		Biology Open Software Suite. <i>Trends Genet</i> 16 , 276-277
1151	62.	Shaik, M. M., Peng, H., Lu, J., Rits-Volloch, S., Xu, C., Liao, M., and Chen, B. (2019)
1152		Structural basis of coreceptor recognition by HIV-1 envelope spike. <i>Nature</i> 565,
1153		318-323
1154	63.	Anumula, K. R., and Taylor, P. B. (1992) A comprehensive procedure for preparation
1155		of partially methylated alditol acetates from glycoprotein carbohydrates. Anal
1156		Biochem 203 , 101-108
1157	64.	Varki, A., Cummings, R. D., Aebi, M., Packer, N. H., Seeberger, P. H., Esko, J. D., Stanley,
1158		P., Hart, G., Darvill, A., Kinoshita, T., Prestegard, J. J., Schnaar, R. L., Freeze, H. H.,
1159		Marth, J. D., Bertozzi, C. R., Etzler, M. E., Frank, M., Vliegenthart, J. F., Lutteke, T.,
1160		Perez, S., Bolton, E., Rudd, P., Paulson, J., Kanehisa, M., Toukach, P., Aoki-Kinoshita, K.
1161		F., Dell, A., Narimatsu, H., York, W., Taniguchi, N., and Kornfeld, S. (2015) Symbol
1162		Nomenclature for Graphical Representations of Glycans. <i>Glycobiology</i> 25 , 1323-1324
1163	65.	Wells, L., Hart, G. W., and Athens Guidelines for the Publication of Glycomics, D.
1164		(2013) Glycomics: building upon proteomics to advance glycosciences. <i>Mol Cell</i>
1165		Proteomics 12 , 833-835
1166	66.	Kahsay, R., Vora, J., Navelkar, R., Mousavi, R., Fochtman, B. C., Holmes, X.,
1167		Pattabiraman, N., Ranzinger, R., Mahadik, R., Williamson, T., Kulkarni, S., Agarwal, G.,
1168		Martin, M., Vasudev, P., Garcia, L., Edwards, N., Zhang, W., Natale, D. A., Ross, K., Aoki-
1169		Kinoshita, K. F., Campbell, M. P., York, W. S., and Mazumder, R. (2020) GlyGen data
1170		model and processing workflow. <i>Bioinformatics</i> 36 , 3941-3943
1171	67.	Tiemeyer, M., Aoki, K., Paulson, J., Cummings, R. D., York, W. S., Karlsson, N. G.,
1172		Lisacek, F., Packer, N. H., Campbell, M. P., Aoki, N. P., Fujita, A., Matsubara, M.,
1173		Shinmachi, D., Tsuchiya, S., Yamada, I., Pierce, M., Ranzinger, R., Narimatsu, H., and
1174		Aoki-Kinoshita, K. F. (2017) GlyTouCan: an accessible glycan structure repository.
1175		<i>Glycobiology</i> 27 , 915-919
1176	68.	York, W. S., Mazumder, R., Ranzinger, R., Edwards, N., Kahsay, R., Aoki-Kinoshita, K.
1177	00.	F., Campbell, M. P., Cummings, R. D., Feizi, T., Martin, M., Natale, D. A., Packer, N. H.,
1178		Woods, R. J., Agarwal, G., Arpinar, S., Bhat, S., Blake, J., Castro, L. J. G., Fochtman, B.,
1179		Gildersleeve, J., Goldman, R., Holmes, X., Jain, V., Kulkarni, S., Mahadik, R., Mehta, A.,
1180		Mousavi, R., Nakarakommula, S., Navelkar, R., Pattabiraman, N., Pierce, M. J., Ross, K.,
1180		Vasudev, P., Vora, J., Williamson, T., and Zhang, W. (2020) GlyGen: Computational
1181		and Informatics Resources for Glycoscience. <i>Glycobiology</i> 30 , 72-73
1182	69.	Madeira, F., Madhusoodanan, N., Lee, J., Tivey, A. R. N., and Lopez, R. (2019) Using
1184	07.	EMBL-EBI Services via Web Interface and Programmatically via Web Services. <i>Curr</i>
1184		Protoc Bioinformatics 66 , e74
1100		

Nivedha, A. K., Makeneni, S., Foley, B. L., Tessier, M. B., and Woods, R. J. (2014)


Importance of ligand conformational energies in carbohydrate docking: Sorting the


1186

1187

70.


1188 wheat from the chaff. *I Comput Chem* **35**, 526-539 1189 Grant, O. C., Xue, X., Ra, D., Khatamian, A., Foley, B. L., and Woods, R. J. (2016) Gly-71. 1190 Spec: a webtool for predicting glycan specificity by integrating glycan array 1191 screening data and 3D structure. *Glvcobiology* **26**, 1027-1028 Peng, W., de Vries, R. P., Grant, O. C., Thompson, A. J., McBride, R., Tsogtbaatar, B., 1192 72. 1193 Lee, P. S., Razi, N., Wilson, I. A., Woods, R. J., and Paulson, J. C. (2017) Recent H3N2 1194 Viruses Have Evolved Specificity for Extended, Branched Human-type Receptors, 1195 Conferring Potential for Increased Avidity. Cell Host Microbe 21, 23-34 1196 73. Gotz, A. W., Williamson, M. J., Xu, D., Poole, D., Le Grand, S., and Walker, R. C. (2012) 1197 Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. 1198 Generalized Born. J Chem Theory Comput 8, 1542-1555 1199 74. Salomon-Ferrer, R., Gotz, A. W., Poole, D., Le Grand, S., and Walker, R. C. (2013) Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. 1200 Explicit Solvent Particle Mesh Ewald. J Chem Theory Comput 9, 3878-3888 1201 1202 75. Kirschner, K. N., Yongye, A. B., Tschampel, S. M., Gonzalez-Outeirino, J., Daniels, C. R., 1203 Foley, B. L., and Woods, R. J. (2008) GLYCAM06: a generalizable biomolecular force 1204 field. Carbohvdrates. I Comput Chem 29, 622-655 1205 Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., and 76. 1206 Simmerling, C. (2015) ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. *J Chem Theory Comput* **11**, 3696-3713 1207 1208 Darden, T. A., and Pedersen, L. G. (1993) Molecular modeling: an experimental tool. 77. *Environ Health Perspect* **101**, 410-412 1209 1210 Brindley, M. A., Chaudhury, S., and Plemper, R. K. (2015) Measles virus glycoprotein 78. 1211 complexes preassemble intracellularly and relax during transport to the cell surface 1212 in preparation for fusion. *J Virol* 89, 1230-1241 1213 Paal, M., Heel, T., Schneider, R., and Auer, B. (2009) A novel Ecotin-Ubiquitin-Tag 79. 1214 (ECUT) for efficient, soluble peptide production in the periplasm of Escherichia coli. 1215 Microb Cell Fact 8,7 Brindley, M. A., and Plemper, R. K. (2010) Blue native PAGE and biomolecular 1216 80. complementation reveal a tetrameric or higher-order oligomer organization of the 1217 1218 physiological measles virus attachment protein H. *J Virol* 84, 12174-12184 1219





Composition


Composition





	was n	ot certified	i by peer i	review) is t	ine author/	funder. It	is mad	avalla
Α	MFVFLVLLPL	- VSS QCVNLTT	RTQLPP <mark>AY</mark> TN	S <mark>F</mark> TRGVYYPD	KVFRS <mark>S</mark> VLHS	TQDLFLPF <mark>F</mark> S	60	С
	NVTWFHAIHV	SGTNGTKRFD	N <mark>PVLP</mark> FNDGV	YFAS <mark>TEK</mark> SNI	IRGWIFGT <mark>T</mark> L	DS <mark>K</mark> TQSLLIV	120	
	NNATNVVIKV	CEF <mark>QF</mark> C <mark>N</mark> DPF	LGV <mark>YYHKNNK</mark>	SWMESEFRVY	SSANNCTFEY	VSQPFLMDLE	180	
	<mark>gkqgn</mark> fknlr	EFVFKNIDGY	FKIYSKHTPI	NLVRDLPQGF	SALEPLVDLP	IGINI <mark>TR</mark> FQT	240	
	LL <mark>ALH<mark>R</mark>SYLT</mark>	PGDSSSGWTA	<mark>GA</mark> AAY <mark>Y</mark> VG <mark>Y</mark> L	QPRTFLLKYN	ENGTITDAVD	CALDPLSETK	300	ti X
	CTLKSF <mark>T</mark> VEK	GIYQTSNFRV	QP <mark>TE</mark> SIVRFP	NITNLCPFGE	VFNA <mark>TR</mark> FASV	YAWNRKRISN	360	
	CVA <mark>D</mark> Y <mark>SV</mark> LYN	S <mark>AS</mark> F <mark>S</mark> TFKCY		CFTNVYADSF	VI <mark>R</mark> GDEV <mark>R</mark> QI	A <mark>PGQTG</mark> KIAD	420	l
	YNYKLPDDFT	GCVIAWNSNN		RBM YLYR <mark>LFRKSN</mark>	LKPFERD <mark>IST</mark>	EIYQAGSTPC	480	
		PL <mark>Q</mark> SYGF <mark>QPT</mark>	NGVGYQPYRV	VVLSFE <mark>LLH</mark> A	PATVCG <mark>PK</mark> KS	T <mark>N</mark> LVKNKCVN	540	
	FNFNGLTGTG	VL <mark>TE</mark> S <mark>NKK</mark> FL	PFQQFGRDIA	DTTDAVRDPQ	TLEILDITPC	SFGGVSVITP	600	
	GTNTSNQVAV	LYQDVNC <mark>TEV</mark>	PVAIHA <mark>DQL</mark> T	PTWRVYSTGS	NVFQTRAGCL	IGA <mark>EHVNN</mark> SY <mark>Y</mark>	660	
	ECDIPIGAGI	CAS <mark>YQT<mark>QTN</mark>S</mark>	PGGSGSVA <mark>SQ</mark>	SI <mark>I</mark> AY <mark>T</mark> MSLG	AENSVAYSNN	SIAIPTNFTI	720	
	SVTTEILPVS	MTKTSVDCTM	YICGDSTECS	NLLLQYGSFC	TQLNRALTGI	AVEQDKNTQE	780	
	VFAQV <mark>KQ</mark> IY <mark>K</mark>	FP TP <mark>PIKD</mark> FGGF	NF <mark>SQ</mark> ILP <mark>DPS</mark>	K <mark>P</mark> SKRSFIED		AG <mark>FIKQ</mark> YG <mark>D</mark> C	840	D
	LGDIAARDLI	L CAQKFNGLTV	LPPLLTD <mark>E</mark> MI	AQYTSALLAG	I TITSGWTFGA	GAALQIPFAM	900	
	<mark>S</mark> QMAYRFNGIG	VTQNVLYENQ	KLIANQFNS A	HR1 IG <mark>K</mark> IQ <mark>D</mark> SL <mark>SS</mark>	TASALGKLQD	VVNQNAQALN	960	ڊ
	TLVKQLSSNF	GAISSVLNDI	LSRLDPPEAE	<mark>F</mark> VQIDRLITGR	LQSLQTYVTQ	QLIRAAEIRA	1020	L54F
	SANLAATKMS	ECVLGQSKRV	DFCG <mark>K</mark> GYHLM	SFPQSAPHGV	VFLHVTY <mark>V</mark> PA	QEKNFTTAPA	1080	 A845S
	ICH <mark>DGK</mark> AHFP	REGVFVS <mark>NGT</mark>	HWFVTQRNFY	EPQIITTDNT	FVS <mark>GNCD</mark> VVI	GIVNN <mark>T</mark> VYDP	1140	A0455 A
	<mark>LQPELD</mark> SFKE	ELDKYFKNHT	SPDVDLGDIS	GINASVVNIQ	HR2 KEIDRLNEVA	KNLNESLIDL	1200	
	-	GGYIPEAPRD	GQAYVRKDGE	WVLLSTFLGG	SHHHHHH		1247	٦
	F			14				
				Key				
	SP SP	= Signal Pept	ide	= NTD =	= N-Ter	rminal Domain		
	= RBD =	= Receptor B	inding Domain	RBM -	= Rece	ptor Binding Mo	otif	
	= FP ==	= Fusion Pep	tide	= HR1 =	= Hepta	ad Repeat 1		
	= HR2 =	= Heptad Rep	eat 2		= Hepta	ad Repeat 2 WT	extent	
	-	= N-glycosite			-	cosite		
	-	•••						
	X	= Variant, no	sequon impact	t <mark>X</mark>	= Varia	nt, sequon abla	ted	
	1	= Furin cleava	ige site in WT	XXX	= Diver	gent region w/ i	nsert	F
	Strikethrough	= Signal Pepti	de	Italics	= "Tag"			-
	-	Antig	en accessibility	u Loget)	XXXXXXXXXXXX	Most		
		Antige	accessionity	. Least/		WOSt		
_								-5
B	▲[D138H]							
_	5 -					Residue Nu	Imber	
2					(Conor)	1250	andei	
Distance to Substitution Site (Å)			He	355Y	S939F	1000 750		
ו Sit					[L:2037]	500 250		
tion								
titu		D253G				# of Sequer	nces	
lsdu 1	0	H146Y	L1203F			• 2 - 5 • 6 - 20		
s '	T761	S151I	D614G			■ 21 - 50 ■ > 9,000		
ce 1	5 1 154F	A845	583D A845S	[5939F]	[L1203F]	3,000		
tanc		1511 L54F (Md45	S939F	T791I	S939F			
		[E583D]	H655Y			Chain Chain Chai	n	
5	₀╷╷╷╡╷╷╷	비비비비	ւս Ֆրիթ	しん しんしん しんしん しんしん しんしん しんしん しんしん しんしん	444	Same chai		
10 20		역 여 아이 영	해야 한 수 위험	的缺的的现	1 다 티 타 바 H			
_0		0 40 10 10	<u> </u>	0 4 5 5 9	4 0. 0. 4			


~ 4

ా స్థాత భాశా భాశా కొత్త లీ సిగ్ ప్రాత్రి రోడి N-Glycosylation Site











Composition

Composition




bicaxiv preprint doi: https://doi.org/AC 2/2020.06.25.172403. this version posted July 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.




В


S Trimer

ACE2



N546





C ACE2 N53* N103 N103 N90 N90 N546